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Abstract 
 
This study was conducted in Omdurman municipality hospitals during the 
period of February 2007 to February 2008 to study the prevalence of 
poliomyelitis virus antibodies in the saliva and sera of OPV immunized 
preschool-aged children using an in-house ELISA. Data concerning history of 
immunization, other medical information and demographic data that collected 
using structural questionnaire with informed consent of the mother or gardian of 
each participant child. One hundred children of 1year to more than 4 years were 
included. Blood and saliva were collected from each child.Positive control 
saliva and sera were obtained from multiple OPV immunized children, whereas 
negative control saliva and sera were obtained from non-OPV immunized 
children and tested in pilot ELISA study. OPV was heat inactivated and used as 
a solid phase antigen for coating the ELISA plates. Goat α Fc human IgA and 
IgG conjugated to (Horse radish peroxidase) HPO were used for the detection of 
salivary IgA and serum IgG respectively. From ELISA pilot studies we 
elaborated an in-house ELISA to study the prevalence of (poliovirus) PV 
specific SIgA and IgG in saliva and sera of OPV immunized children. Several 
factors that could affect IgA, IgG, and IgA/IgG ratio were investigated in this 
study such as age, sex, and area of residence. 
In this study the prevalence of polio virus specific salivary IgA and serum 
IgG were detected in the various age groups of OPV immunized children. The 
absorbance values of polio virus specific salivary IgA and serum IgG were very 
high in all age groups. However, the differences between these values among all 
age groups were not statistically significant. The P value for IgA was (0.36) and 
for IgG the P value was (0.20). Furthermore, children who received two or five 
doses of OPV had the same absorbance values for IgA and IgG. Moreover, 
salivary IgA /serum IgG absorbance values ratio in all age groups were also 
non-statistically significant (P = 0.45). These results clearly demonstrated that 
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OPV induced both local and systemic Abs responses in all immunized children. 
Moreover, the prevalence of polio virus specific salivary IgA and serum IgG 
was the same in both sex. Absorbance values for PV specific salivary IgA was 
relatively high in comparison with PV specific IgG in both sex, but these 
differences were not statistically significant (P = 0.294 for IgA and P = 0.255 
for IgG) for both isotypes. However, significantly higher salivary IgA/serum 
IgG absorbance ratio were found in males than in females (P = 0.03).  
OPV immunized children from various area of residences had high 
prevalence PV specific salivary IgA and serum IgG. However, the absorbance 
values of salivary IgA were relatively higher in comparison with polio virus 
specific serum IgG. However, these absorbance differences were not 
statistically significant among children of various area of residences for both 
isotypes (P = 0.383 for IgA and P = 0.276 for IgG), salivary IgA/ serum IgG 
absorbance ratio were statistically not significant as well (P = 0.058). 
A linear relationship between salivary IgA and serum IgG was found and 
OPV immunization armament children with local and systemic Abs responses 
that make it difficult for wild virus to escape any of the two lines of defense. 
In this study we concluded that OPV immunization in childhood produces 
both local and systemic Abs response. The number of doses of OPV, age, sex 
and area of residence had no significant effect (P>0.05) on the value of salivary 
IgA and IgG, whereas sex had a significant effect on the salivary IgA/ serum 
IgG ratio. Our in-house ELISA is a useful tool for monitoring OPV 
immunization campaigns for the eradication of poliomyelitis. 
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  ﻤﻠﺨﺹ ﺍﻷﻁﺭﻭﺤﺔ
  
 ﺇﻟـﻲ ﻓﺒﺭﺍﻴـﺭ 7002ﺃﺠﺭﻴﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺒﻤﺴﺘﺸﻔﻴﺎﺕ ﺍﻷﻁﻔﺎل ﺒﺄﻤﺩﺭﻤﺎﻥ ﻓﻲ ﺍﻟﻔﺘﺭﺓ ﻤﻥ ﻓﺒﺭﺍﻴﺭ   
ﻡ ﻟﺩﺭﺍﺴﺔ ﻤﺴﺘﻭﻱ ﺍﻷﺠﺴﺎﻡ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﺨﺎﺼﺔ ﺒﻔﻴﺭﻭﺱ ﺸﻠل ﺍﻷﻁﻔﺎل ﺍﻟﻤﺘﻭﺍﺠﺩﺓ ﻓﻲ ﻟﻌﺎﺏ ﻭﻤـﺼل 8002
  . ﺍﻟﻤﺩﺭﺴﻲ ﻭﺫﻟﻙ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺍﺨﺘﺒﺎﺭ ﺍﻻﻟﻴﺯﺍ ﻏﻴﺭ ﺍﻟﻤﺒﺎﺸﺭﺍﻷﻁﻔﺎل ﺍﻟﺫﻴﻥ ﺍﻋﻤﺎﺭﻫﻡ ﻤﺎ ﻗﺒل ﺍﻟﺴﻥ
ﺠﻤﻌﺕ ﺍﻟﺒﻴﺎﻨﺎﺕ ﺍﻟﺨﺎﺼﺔ ﺒﺘﺎﺭﻴﺦ ﺍﻟﺘﺤﺼﻴﻥ، ﻤﻌﻠﻭﻤﺎﺕ ﻁﺒﻴﺔ ﻭﺒﻴﺎﻨﺎﺕ ﻋﻥ ﻤﺤل ﺍﻷﻗﺎﻤﺔ، ﺍﺴـﺘﺨﺩﻡ   
  .ﻓﻲ ﺫﻟﻙ ﺍﺴﺘﺒﻴﺎﻥ ﻤﻠﻲ ﺒﻭﺍﺴﻁﺔ ﺍﻻﻡ ﺃﻭ ﻭﻟﻲ ﺍﻷﻤﺭ ﻟﻜل ﻁﻔل ﻤﺸﺎﺭﻙ
 ﺴﻨﻭﺍﺕ، 4 ﺍﻜﺜﺭ ﻤﻥ  ﺍﻟﻲ 1ﺘﻡ ﺠﻤﻊ ﻋﻴﻨﺎﺕ ﺍﻟﻤﺼل ﻭﺍﻟﻠﻌﺎﺏ ﻤﻥ ﻤﺎﺌﺔ ﻁﻔل ﺘﺘﺭﺍﻭﺡ ﺃﻋﻤﺎﺭﻫﻡ ﻤﻥ   
ﺍﺴﺘﻌﻴﻥ ﺒﻠﻌﺎﺏ ﻭﻤﺼل ﻤﺭﺠﻌﻴﻥ ﺇﻴﺠﺎﺒﻴﻴﻥ ﺘﻡ ﺃﺨـﺫﻫﻡ ﻤـﻥ (. ﺩﻡ ﻭﻟﻌﺎﺏ )ﺤﻴﺙ ﺍﺨﺫ ﻤﻥ ﻜل ﻁﻔل ﻋﻴﻨﺘﺎﻥ 
ﺍﻁﻔﺎل ﻟﻘﺤﻭﺍ ﻤﺭﺍﺕ ﻋﺩﻴﺩﺓ ﻭﻤﻨﺘﻅﻤﺔ ﺒﻠﻘﺎﺡ ﺸﻠل ﺍﻷﻁﻔﺎل، ﻜﻤﺎ ﺃﻴﻀﺎ ﺍﺴﺘﺨﺩﻡ ﻟﻌـﺎﺏ ﻭﻤـﺼل ﻤـﺭﺠﻌﻴﻥ 
  . ﺭﺽ ﺒﻌﺩﺴﻠﺒﻴﻴﻥ ﻟﻼﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ ﺠﻤﻌﻭﺍ ﻤﻥ ﺍﻁﻔﺎل ﻟﻡ ﻴﺘﻠﻘﻭﺍ ﺃﻱ ﺠﺭﻋﺎﺕ ﻭﻟﻡ ﻴﺼﺎﺒﻭﺍ ﺒﺎﻟﻤ
 ﺴﺎﻋﺔ ﻻﺴﺘﺨﺩﺍﻤﻪ ﻜﺄﻨﺘﺠﻴﻥ 1/2ﻟﻤﺩﺓ ( ﻡo65)ﺘﻡ ﺘﻀﻌﻴﻑ ﻟﻘﺎﺡ ﺸﻠل ﺍﻷﻁﻔﺎل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﺘﺴﺨﻴﻥ   
 ﻟﻼﻨـﺴﺎﻥ GgI ﻭ AgIﻗﺭﻥ ﺍﻟﺠـﺯﺀ ﺍﻟﺒﻠـﻭﺭﻱ ﻟـﺼﻨﻑ . ﻓﻲ ﺍﻟﺘﺠﺭﺒﺔ ﻴﺘﻡ ﺍﻤﺘﺼﺎﺼﻪ ﺒﻭﺍﺴﻁﺔ ﺍﻟﻁﺒﻕ 
 ﻓﻲ ﻟﻌﺎﺏ ﻭﻤـﺼل ﺍﻷﻁﻔـﺎل GgI ﻭ AgI ﻭﺃﺴﺘﻌﻤل ﻟﻠﻜﺸﻑ ﻋﻥ OPHﺍﻟﻤﺤﻀﺭ ﻓﻲ ﺍﻟﻤﺎﻋﺯ ﻤﻊ ﺃﻨﺯﻴﻡ 
  .ﺩ ﺍﻟﻤﺭﺽ ﻋﻠﻲ ﺍﻟﺘﻭﺍﻟﻲﺍﻟﻤﺤﺼﻨﻴﻥ ﻀ
 ﻤﺴﺘﻭﻱ ﺍﻻﺠﺴﺎﻡ ﺍﻟﻤـﻀﺎﺩﻩ  ﺘﻤﺕ ﺩﺭﺍﺴﻪ ﺍﻟﻌﺩﻴﺩ ﻤﻥ ﺍﻟﻌﻭﺍﻤل ﺍﻟﺘﻲ ﻴﻤﻜﻥ ﺍﻥ ﻴﻜﻭﻥ ﻟﻬﺎ ﺘﺎﺜﻴﺭ ﻋﻠﻲ   
ﻤﻥ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺘـﻡ ﺍﻟﻜـﺸﻑ ﻋـﻥ   . ﺍﻟﻤﺼﻠﻲGgI / ﺍﻟﻠﻌﺎﺒﻲAgIﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﺨﺎﺼﺔ ﺒﺎﻟﻤﺭﺽ ﻭﻤﻌﺩل 
ﻓـﻲ ﺍﻷﻁﻔـﺎل  ﺍﻟﻤﺼﻠﻲ ﻟﻔﻴﺭﻭﺱ ﺸﻠل ﺍﻷﻁﻔﺎل ﻓﻲ ﻓﺌﺎﺕ ﻋﻤﺭﻴـﺔ ﻋﺩﻴـﺩﺓ GgI ﺍﻟﻠﻌﺎﺒﻲ ﻭ AgIﺍﻨﺘﺸﺎﺭ 
ﺍﻟﻤﺤﺼﻨﻴﻥ ﻭﻗﺩ ﻭﺠﺩ ﺃﻥ ﻗﻴﻤﺔ ﺍﻟﻜﺜﺎﻓﻪ ﺍﻟﻀﻭﺌﻴﺔ ﻟﻼﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﻩ  ﻤﺭﺘﻔﻌﺔ ﻓﻲ ﻜل ﺍﻟﻔﺌﺎﺕ ﺍﻟﻌﻤﺭﻴﺔ ﻭﻤﻥ ﺜﻡ 
 AgI ﻟـﺼﻨﻑ eulav Pﻓﺄﻥ ﺍﺨﺘﻼﻓﺎﺕ ﺍﻟﻘﻴﻡ ﻟﻡ ﺘﻜﻥ ﺫﺍﺕ ﻗﻴﻤﺔ ﺇﺤﺼﺎﺌﻴﺔ ﻤﻌﻨﻭﻴﺔ ﻤﻬﻤﺔ، ﺤﻴﺙ ﺃﻥ ﻗﻴﻤـﺔ 
ل ﺍﻟﺫﻴﻥ ﺘﻠﻘﻭﺍ ﺠﺭﻋﺘﻴﻥ ﺒﺎﻻﻀﺎﻓﺔ ﻟﺫﻟﻙ، ﻓﺄﻥ ﺍﻷﻁﻔﺎ (. 0.02) ﺍﻟﻤﺼﻠﻲ GgIﻭﻟﺼﻨﻑ ( 0.63)ﺍﻟﻠﻌﺎﺒﻲ ﻫﻲ 
 .GgI ﻭﺼﻨﻑ AgI ﺠﺭﻋﺎﺕ ﻤﻥ ﻟﻘﺎﺡ ﺸﻠل ﺍﻷﻁﻔﺎل ﻜﺎﻨﺕ ﻟﺩﻴﻬﻡ ﻨﻔﺱ ﻗﻴﻡ ﺍﻟﻜﺜﺎﻓﻪ ﺍﻟﻀﻭﺌﻴﻪ ﻟﺼﻨﻑ 5ﺃﻭ 
  .)54.0=P( ﺍﻟﻤﺼﻠﻲ ﻓﻲ ﻜل ﺍﻟﻔﺌﺎﺕ ﺍﻟﻌﻤﺭﻴﺔ ﻟﻴﺱ ﺫﺍﺕ ﻗﻴﻤﺔ ﻤﻌﻨﻭﻴﺔ GgI/  ﺍﻟﻠﻌﺎﺒﻲ AgIﻜﻤﺎ ﺍﻥ ﻤﻌﺩل 
ﺠﺎﺒﺔ ﺍﻟﻤﻨﺎﻋﻴـﺔ ﺍﻭﻀﺤﺕ ﻫﺫﻩ ﺍﻟﻨﺘﺎﺌﺞ ﺃﻥ ﻟﻘﺎﺡ ﺸﻠل ﺍﻷﻁﻔﺎل ﻴﻌﻤل ﻋﻠﻰ ﺤﺙ ﻜـل ﻤـﻥ ﺍﻻﺴـﺘ   
ﺇﻀﺎﻓﺔ ﻟﺫﻟﻙ ﻓﺄﻥ ﻤﺴﺘﻭﻱ ﺍﻻﺠﺴﺎﻡ ﺍﻟﻀﺎﺩﻩ ﻟﻔﻴـﺭﻭﺱ . ﺍﻟﻤﻭﻀﻌﻴﺔ ﻭﺍﻟﺠﻬﺎﺯﻴﺔ ﻓﻲ ﻜل ﺍﻷﻁﻔﺎل ﺍﻟﻤﺤﺼﻨﻴﻥ 
 AgI ﺍﻟﻤﺼﻠﻲ ﻓﻲ ﻜﻼ ﺍﻟﺠﻨﺴﻴﻥ ﻤﺘﻘﺎﺭﺒﺔ ﺠﺩﺍﹰ ﺒـﺎﻟﺭﻏﻡ ﻤـﻥ ﺃﻥ ﻗـﻴﻡ GgI ﺍﻟﻠﻌﺎﺒﻲ ﻭ AgIﺸﻠل ﺍﻷﻁﻔﺎل 
ﻼﻑ ﺃﻴﻀﺎﹰ ﻟﻴﺱ ﺫﻭ ﻗﻴﻤﺔ  ﺍﻟﻤﺼﻠﻲ ﻓﻲ ﻜﻼ ﺍﻟﺠﺴﻴﻥ ﺇﻻ ﺃﻥ ﻫﺫﺍ ﺍﻻﺨﺘ GgIﺍﻟﻠﻌﺎﺒﻲ ﺃﻋﻠﻰ ﻨﺴﺒﻴﺎﹰ ﻤﻘﺎﺭﻨﺔ ﻤﻊ 
 ﻜﻤﺎ ﺍﻥ ﻤﻌﺩل ﺍﻟﻜﺜﺎﻓﻪ ﺍﻟﻀﻭﺌﻴﺔ GgI ﻟﺼﻨﻑ )552.0=P( AgI ﻟﺼﻨﻑ )492.0 =P(ﺇﺤﺼﺎﺌﻴﺔ ﻤﻌﻨﻭﻴﺔ 
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ﻜﻤـﺎ ﻭﻀـﺤﺕ . )30.0 =P( ﺍﻟﻤﺼﻠﻲ ﻤﺭﺘﻔﻌﺔ ﻓﻲ ﺍﻟﺫﻜﻭﺭ ﻋﻨﻪ ﻓﻲ ﺍﻷﻨـﺎﺙ GgI/  ﺍﻟﻠﻌﺎﺒﻲ AgI ﻟـ
ﻤﻨـﺎﻁﻕ ﺍﻟـﺴﻜﻨﻴﺔ ﺍﻟﺩﺭﺍﺴﺔ ﺃﻥ ﺍﻨﺘﺸﺎﺭ ﺍﻟﻤﺴﺘﻀﺩﺍﺕ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻟﻔﻴﺭﻭﺱ ﺸﻠل ﺍﻷﻁﻔﺎل ﻤﺭﺘﻔﻊ ﻓﻲ ﻤﺨﺘﻠﻑ ﺍﻟ 
 ﺍﻟﻤﺼﻠﻲ، ﻭﺍﻴﻀﺎ ﻓﺎﻥ ﺍﺨﺘﻼﻑ ﻫﺫﻩ ﺍﻟﻘﻴﻡ ﻟﻴﺱ GgI ﺍﻟﻠﻌﺎﺒﻲ ﻤﺭﺘﻔﻌﺔ ﻨﺴﺒﻴﺎﹰ ﻤﻘﺎﺭﻨﺔ ﺒﺼﻨﻑ AgIﻭﻟﻜﻥ ﻗﻴﻡ 
 GgI  ﻟـ  ـ)672.0 =P( ﻭAgI  ﻟـ  ـ)383.0 =P(ﺫﻭ ﺃﻫﻤﻴﺔ ﻤﻌﻨﻭﻴﺔ ﻋﻠﻰ ﻤﺴﺘﻭﻱ ﺍﻟﻤﻨﺎﻁﻕ ﺍﻟـﺴﻜﻨﻴﺔ 
ﺍﻭﻀـﺤﺕ . )850.0 =P( ﺍﻟﻤﺼﻠﻴﻠﻡ ﻴﻜﻥ ﺫﺍ ﺃﻫﻤﻴﺔ ﺍﺤﺼﺎﺌﻴﺔ ﻤﻌﻨﻭﻴﺔ GgI/  ﺍﻟﻠﻌﺎﺒﻲ AgIﻭﻜﺫﻟﻙ ﻤﻌﺩل 
  ﻜﻤﺎ ﺍﻭﻀـﺤﺕ ﺃﻥ GgI ﻭ ﺍﻟﺠﺴﻡ ﺍﻟﻤﻀﺎﺩ  AgIﺍﻟﺩﺭﺍﺴﺔ ﺃﻥ ﻫﻨﺎﻟﻙ ﻋﻼﻗﺔ ﻁﺭﺩﻴﺔ ﺒﻴﻥ ﺍﻟﺠﺴﻡ ﺍﻟﻤﻀﺎﺩ 
ﺍﻟﺘﻠﻘﻴﺢ ﺒﺎﺴﺘﺨﺩﺍﻡ ﻟﻘﺎﺡ ﺸﻠل ﺍﻷﻁﻔﺎل ﻴﻌﻤل ﻋﻠﻰ ﺤﺙ ﺍﻻﺴﺘﺠﺎﺒﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﻤﻭﻀـﻌﻴﺔ ﻭﺍﻟﺠﻬﺎﺯﻴـﺔ ﻤﻤـﺎ 
  . ﻴﺼﻌﺏ ﻋﻠﻰ ﺍﻟﻔﻴﺭﻭﺱ ﺍﻟﻀﺎﺭﻱ ﺘﺨﻁﻲ ﺩﻓﺎﻋﺎﺕ ﺍﻟﺠﺴﻡ ﺒﻨﻭﻋﻴﻬﺎ
ﻜﻤـﺎ ﺍﻥ  ،  ﺃﻥ ﻟﻘﺎﺡ ﺸﻠل ﺍﻷﻁﻔﺎل ﻴﻌﻤل ﻋﻠﻰ ﺤﺙ ﺍﻻﺴﺘﺠﺎﺒﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻤﻥ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻨﺴﺘﺨﻠﺹ 
ﻋﺩﺩ ﺠﺭﻋﺎﺕ ﺍﻟﻠﻘﺎﺡ، ﻋﻤﺭ ﺍﻟﻁﻔل، ﺍﻟﺠﻨﺱ ﻭﺍﻟﻤﻨﻁﻘﺔ ﺍﻟﺴﻜﻨﻴﺔ ﻟﻴﺴﺕ ﻟﻬﺎ ﺃﻴﺔ ﺃﻫﻤﻴـﺔ ﻤﻌﻨﻭﻴـﺔ ﺍﺤـﺼﺎﺌﻴﺔ 
 ﻋﻠﻰ ﻤﺴﺘﻭﻱ ﺍﻻﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﻩ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﺨﺎﺼﺔ ﺒﺎﻟﻤﺭﺽ ﺒﻴﻨﻤﺎ ﺠﻨﺱ ﺍﻟﻁﻔل ﻟﻪ ﺘﺄﺜﻴﺭ ﻋﻠﻰ )50.0>P(
ﺍﻋﺘﺒﺭﺕ ﺘﻘﻨﻴﺔ ﺍﻻﻟﻴﺯﺍ ﻏﻴﺭ ﺍﻟﻤﺒﺎﺸﺭﺓ ﻜﻭﺴﻴﻠﺔ ﻨﺎﻓﻌﺔ ﻟﺘﻘﻴـﻴﻡ ﺃﻫﻤﻴـﺔ . ﺍﻟﻤﺼﻠﻲ GgI / ﺍﻟﻠﻌﺎﺒﻲ AgIﻤﻌﺩل 
  .ﺍﻟﺘﻠﻘﻴﺢ ﻻﺴﺘﺌﺼﺎل ﺸﻠل ﺍﻷﻁﻔﺎل
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Introduction 
 Poliomyelitis is an acute viral infection which range in severity from non 
specific illness to paralysis with permanent disability. Humans are the sole 
reservoir for poliovirus. Wild poliovirus (WPV) spreads directly or indirectly 
from person to person .Virus dissemination is facilitated by poor sanitation in 
all countries, and less hygiene facilitates fecal-oral and oral-oral (mouth-fingers-
mouth) transmission. There are three poliovirus serotypes with minimum 
heterotypic immunity between them and immunity is permanent to the type 
causing the infection (Ryan and Ray, 2004). Following natural exposure, IgM 
and IgG appear in the serum about 7-10 days after infection. Sufficiently high 
levels of antibodies can block poliovirus entry to the (CNS). 
Long last immunity is induced by vaccination. Both live and killed 
vaccines are available .The Salk type inactivated vaccine (IPV), contains the 
three serotypes and protection correlate with presence of serum IgG antibodies. 
On the other hand the Sabin type live attenuated oral poliovirus vaccine (OPV) 
is also a trivalent vaccine. OPV gives live long immunity and the only type of 
vaccine used in immunization programme in the Sudan. The vaccine induces 
mucosal immunity, where SIgA is the protective isotype as well as systemic 
IgG. A major campaign by WHO is underway to eradicate poliovirus from the 
world as was done for smallpox virus. In Sudan the poliovirus eradication 
programme initiated in 1994 and annual national immunization days have been 
organized (Rayne and Ray, 2004). With the development of a comprehensive 
national plan recently, part of the global initiation to eradicate poliomyelitis, 
Federal Ministry health conducted five rounds of a national polio immunization 
campaign in 2007, and one sub national immunization round. 
 
xvi 
 
The present study was designed to fulfill the following objectives: 
• To measure the level of neutralizing Abs in sera of preschool aged children 
using in- house ELISA. 
• To determine the level of specific poliovirus salivary IgA as a method for 
measuring mucosal immunity to OPV. 
• To determine whether oral polio virus vaccine confer sufficient immunity to 
protect children from wild polio virus infection.  
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Chapter One 
Literature Review 
 
1.1 Poliomyelitis 
Poliomyelitis, often called infantile paralysis is a highly contagious 
viral infectious disease caused by three types of polio virus that enter the 
central nervous system, infecting and destroying motor neurons leading to 
muscle weakness and acute flaccid paralysis. The term poliomyelitis derived 
from a Greek word, polio meaning “grey”, Mylon referring to the “spinal 
cord” and "It is" which means inflammation. (Chamberlin and Narins, 
2005).  
    
1.2 History of poliomyelitis  
The effects of polio have been known since prehistory. Egyptian 
paintings and carvings depict otherwise healthy people with withered limbs, 
and children walking with canes at a young age (Paul, 1971). The first 
clinical description was provided by the British physician Michael 
Underwood in 1793, where he refers to polio as debility of the lower 
extremities .The work of physicians Jakob Heine in 1840 and Karl Oskar 
Medin in 1890 led to it being known as Heine-Medin disease. The disease 
was later called infantile paralysis, based on its propensity to affect children 
(Pearce, 2005).Before the 20th century, polio infections were rarely seen in 
infants before six months of age, most cases occurring in children six 
months to four years of age (Robertson, 1993). Poorer sanitation of that time 
resulted in a constant exposure to the virus, which enhanced a natural 
immunity within the population. In developed countries during the late 19th 
and early 20th centuries, improvements were made in community sanitation, 
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including better sewage disposal and clean water supplies. Paradoxically 
these changes drastically increased the proportion of children and adults at 
risk of paralytic polio infection, by reducing childhood exposure and 
immunity to the disease. The polio epidemics changed not only the lives of 
those who survived them, but also affected profound cultural changes; 
spurring grassroots fund-raising campaigns that would revolutionize medical 
philanthropy, and giving rise to the modern field of rehabilitation therapy. 
As one of the largest disabled groups in the world, polio survivors also 
helped to advance the modern disability rights movement through campaigns 
for the social and civil rights of the disabled. The World Health Organization 
estimates that there are 10 to 20 million polio survivors worldwide. In 1977 
there were 254,000 persons living in the United States who had been 
paralyzed by polio. According to doctors and local polio support groups, 
some 40,000 polio survivors with varying degrees of paralysis live in 
Germany, 30,000 in Japan, 24,000 in France, 16,000 in Australia, 12,000 in 
Canada and 12,000 in the United Kingdom .Many notable individuals have 
survived polio and often credit the prolonged immobility and residual 
paralysis associated with polio as a driving force in their lives and 
careers(Bruno ,2002). The disease was very well publicized during the polio 
epidemics of the 1950s, with extensive media coverage of any scientific 
advancement that might lead to a cure.  
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1.3 Etiology of the disease 
Polio virus is an enterovirus belongs to Picorna family. It’s a small 
RNA virus with non-enveloped capsid (Ryan& Ray, 2004). The genome is 
limited and only large enough to encode about 10 genes which in turn 
encode small number of viral proteins critical for invasion and replication of 
the virus with in human cells. There are three different sero types of polio 
virus (pv1, pv2 and pv3) each with slightly different capsid proteins, but 
each produces the same disease symptoms (Ryan& Ray, 2004). PV1 is the 
most common in nature; however, all the tree forms are extremely virulent. 
1.4 Poliovirus receptor 
Poliovirus interacts with its receptor poliovirus receptor (PVR), also 
known as CD155 on human cells, which function to gain entry into the cell. 
CD155 is expressed by various cells, including monocytes, macrophages, 
thymocytes, CNS neurons, M-cells, B-cells, and follicular dendritic cells 
(Janeway etal., 2001; Iwasaki etal., 2002). CD155 has three extracellular 
immunoglobulin-like domains: a transmembrane domain, and a cytoplasmic 
domain. The two types of CD155 resulting from alternative splicing and 
differ only in the length of their cytoplasmic regions. Immunoglobulin 
domain 1 contains the sites of viral binding, while the other two extracellular 
domains play a minor role in affinity (Racanicello, 1996). The binding 
region of domain (1) is known as the C’-C” ridge, and interacts with VP1, 
VP2, and VP3 (Belnap etal., 2000). Each type of polio strain binds to the 
receptor somewhat differently, as some mutations will allow one strain to 
bind but not others. Certain regions of the virus are important to receptor 
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ligation. A distinctive peak on one axis of the poliovirus is surrounded by a 
wide, deep chasm named ‘the canyon’. This area is where the C’-C” ridge of 
the receptor inserts and binds. Ligation occurs at multiple locations, as 
mutations at various points in this area reduce affinity. Following ligation, 
CD155 induces structural changes in the poliovirus, creating an altered virus 
commonly called the A particle or 135S state. In this state, the N terminus of 
VP1, as well as VP4, is expressed on the viral surface as opposed to inside 
the virus (Belnap etal., 2000). In addition, this form is more sensitive to 
proteases. These changes give the viral coat a hydrophobic character, 
allowing it to insert in the host cell membrane. Researches strongly suggest 
that this creates a transmembrane pore in the host cell. After a VP3 plug is 
removed, RNA can leave the viral capsid and enter the cytoplasm of the host 
cell (Belnap etal., 2000). Here the virus replicates and causes cell lysis, 
continuing the spread to other cells. It has also been proposed that when 
CD155 binds in the viral canyon, it disrupts a hydrocarbon binding pocket, 
decreasing sphigosine affinity to the pocket. Subsequent release of 
sphigosine destabilizes the capsid, aiding the release of viral RNA 
(Racaniello, 1996). Data has indicated that a physical association between 
CD44 and CD155 exists and that CD44 may able to transduce an apoptotic 
signal to the host cell on which it is located, contributing to lysis and cell 
damage. Additionally, anti-CD44 may be able to block virus binding to 
CD155 because of the close proximity of the two transmembrane proteins 
(Gosselin etal., 2003). However, some studies show that CD44's presence 
has no effect on the binding affinity of poliovirus to CD155, nor does it 
affect the replication of poliovirus (Racaniello, 1996). As of yet, the role of 
CD44 in poliovirus is still unknown.  
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1.5 Poliovirus sero types 
There are three serotypes of poliovirus, PV1 (Mahoney or Brunhilde), 
PV2 (Lansing), and PV3 (Leon); each with a slightly different capsid 
proteins. Capsid proteins define cellular receptor specificity and virus 
antigenicity. PV1 is the most common form encountered in nature, however 
all three forms are extremely infectious(Paul,1971) .Also all  the three forms 
of poliovirus are structurally similar to other human enteroviruses, 
coxsackieviruses, echoviruses, and to human rhinoviruses, which also use 
immunoglobulin-like molecules to recognize and enter host cells(He, etal 
,2003). Phylogenetic analysis of the RNA and protein sequences of 
poliovirus suggests that PV may have evolved from a C-cluster coxsackie 
(A) virus ancestor, arising through a mutation within the capsid. The distinct 
speciation of poliovirus probably occurred as a result of change in cellular 
receptor specificity from intercellular adhesion molecule-1-(ICAM-1) used 
by C-cluster coxsackie (A) viruses to CD155; leading to a change in 
pathogenicity, and allowing the virus to infect nervous tissue. 
 
 
                     
 6
                       
Fig (1.1) Poliovirus receptor (Hogle, 1985) 
 
 
 
1.6 Genetics of poliovirus 
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Antigenic sites recognized by monoclonal antibodies with neutralizing 
activity for the Sabin vaccine strains of poliovirus of serotypes 1, 2 and 3 
have been studied by the isolation and characterization of mutants resistant 
to neutralization by antibody. Three distinct sites have been identified which 
are designated site 1, site 2 and site 3. Site 1 includes a region of 12 amino 
acids of VP1, from residues 89 to 100, and a corresponding region of VP1 
has been identified as an antigenic site for poliovirus 2. This site was 
strongly immunodominant in type 2 and type 3 but was not detected for 
poliovirus 1. Site 2 is a complex site including residues 220 to 222 from VP1 
with residues including 169 and 170 and others of VP2. Both site  2a and site 
2b have been detected in type 1 poliovirus, while as yet only site 2b has been 
detected in type 3 poliovirus. Site 3 is a complex site including residues 286 
to 290 from VP1 with residues including 58 and 59 and others of VP3. Both 
sites 3a and 3b have been detected in type 3 poliovirus, while as yet only site 
3b has been detected in type 1 poliovirus. In fig (1.2), non-coding regions are 
shown as empty boxes, regions that encode structural capsid proteins are 
shown in dark blue and regions that encode non-structural proteins are 
shown in light blue. The RNA genome is ~7500 bases in length, the 5' end is 
covalently linked to the virus encoded protein VPG, and the 3' end possesses 
a polyadenylate tail shown as AAAAAA (Minor, 1999).      
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Fig (1.2) the organization of the poliovirus genome (Minor, 1999)  
 
 
 
 
1.7 Life cycle of poliovirus 
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1.7.1 Entry of poliovirus 
Poliovirus enters the human body either through the nose or mouth, 
and then proceeds into the digestive tract. If the virus survives the harsh 
conditions of the stomach, it can infect the cells lining the intestine: the gut 
mucosa. In the gut mucosa, the virus infects cells and replicates. While the 
exact mechanism of infection remains uncertain, Payer's Patches, which are 
nodules consisting of thirty to forty organized lymphoid follicles in the sub 
mucosal layer of the intestinal lining, have been implicated in this process 
 1.7.2 Attachment/ Absorption  
The capsid of poliovirus is composed of an icosahedral arrangement 
of 60 protomers, each containing polypeptides VP1, VP2, VP3, and VP4, 
which were all derived from cleavage of original protomer VP0. The virus 
binds to the host cell receptor, requiring interaction of the viral binding site 
with the host cell receptor.  
The specific binding site on poliovirus involves VP1, VP2 and VP3 
which interact with host cell receptor CD155, an immunoglobulin-like 
molecule with 3 domains. Viral attachment involves 'dual tropism'; the virus 
infects primate cells of three distinct cell types: lymphoid and epithelial cells 
in the gut and neurons in the CNS. Following binding the viral RNA is 
released into the cytoplasm of the host cell through a membrane channel. 
 
 
1.7.3 Uncoating of the virus 
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          Binding between the virus and its receptor leads to conformational 
changes in the capsid. VP4, an internal capsid protein detaches from the 
capsid. The capsid swells and the poliovirus genome is susceptible to 
degradation. When VP1 is released, the genome is released onto the 
cytoplasm of the cell. The viral entry strategy is very inefficient; only 1% of 
the viruses initiate an infection. 
1.7.4 "Shut-off" of host cell macromolecular synthesis  
Following entering of the virus the host cell protein synthesis and 
RNA synthesis are inhibited. This is due to cleavage of the cap-binding 
complex (CBC) that is required of all eukaryotic mRNA's during initiation 
of translation. This process serves a dual function: to free up more ribosome 
to translate the viral genomes, and second, to ensure that the cell will break 
down and die, ultimately releasing the newly assembled viral particles. This 
is initiated at approximately half of an hour after infection, and within two 
hours, a sharp decrease in cellular macromolecular synthesis can be 
observed. 
1.7.5 Synthesis of viral components  
          Poliovirus is a positive- sense single stranded RNA virus, meaning the 
RNA is of the same polarity, or sense, as mRNA. Thus, viral RNA is able to 
code for all the proteins needed during replication and it is infectious itself. 
The central player in replication of RNA viruses is the viral RNA-dependent 
RNA polymerase. The 53 kDa poliovirus polymers, together with other viral 
and possibly host proteins, carry out viral replication in the host cell 
cytoplasm. Synthesis is initiated approximately 2.5 to 3 hours after infection 
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takes place. This process involves protein synthesis, protein processing, and 
RNA replication of the viral genome. 
1.7.6 RNA replication                                        
      Replication occurs entirely in the cytoplasm. In addition to serving as a 
template for protein synthesis, the positive sense strand genome is utilized as 
a template for the synthesis negative sense strands. Host cells lack the 
necessary machinery to replicate RNA. Poliovirus uses a viral RNA-
dependent RNA polymerase to produce RNA molecules of the opposite 
polarity. Viral protein VPg covalently attached to uridine (VPg-UUU) serves 
as the primer. The first round of replication produces a single anti sense 
molecule. This antisense template is then used to produce sense copies of the 
original genome that can be packaged into viral capsid prior to viral release. 
New genome formation sends messages to the cell's translation machinery, 
leading to a high level of viral protein production fig (1.3) 
1.7.7 Protein Synthesis and Processing 
          The rise in protein synthesis after 2 hours in infected cells is due to 
viral protein production. As the poliovirus genome is made of positive sense 
single stranded RNA, The genome encodes a single 'polyprotein' of between 
2100-2400 AA's. Both ends of the genome are modified, the 5' end by a 
covalently attached small, basic protein VPg (~23 AA's), the 3' end by 
polyadenylation. In a series of cleavages, viral proteases cleave themselves 
out and break down the polyprotein into 10 separate gene products involved 
in replication and packaging fig(1.3) The viral proteases 2A cleave the p220 
subunit of the cap binding complex (eIF4F subunit of eIF4G), making host 
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cell mRNA unrecognizable to ribosome. As a result, the 2A protease 
abrogates most of the host cell's own protein synthesis. Doing so increases 
the number of free ribosome to translate viral RNA and insures that the cell 
will break down, releasing progeny viruses. Viral mRNA relies on a 5' UTR 
containing a 'clover-leaf' secondary known as an internal ribosome entry site 
(IRES) that serves as a ribosome docking site to the 40S subunit of ribosome 
fig (1.4). The 5' methyl-guanosine cap attached to host mRNA for ribosome 
recognition is unnecessary in poliovirus, allowing for viral RNA translation. 
The primary attenuating mutation in the Sabin vaccine is located in the 
IRES. While Sabin poliovirus can replicate efficiently in gut epithelial 
tissues (primary site of replication), it is unable to replicate efficiently in the 
nervous system. 
1.7.8 Viral assembly 
          The newly synthesized RNA is packaged inside a capsid. Viral 
particles are assembled through morphogenesis, and proteolytic cleavage of 
the capsid protein forms the final particle: a P1 polyprotein precursor is 
cleaved into a protomer composed of viral proteins, which unite together and 
envelop the viral RNA. Assemblage occurs 4-6 hours after infection fig. 
(1.3). 
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              Fig. (1.3) Polio virus life cycle (De Jesus, 2007) 
 
1.7.9 Viral Release 
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      Maturation of the virus involves cleavage of viral proteins; particles are 
then released from the host cell via cell lysis. This is most likely due to a 
'preprogrammed' event which takes place after a particular time after "shut-
off" of host cell protein synthesis and RNA synthesis. The free viral particles 
are now allowed to infect other host cells. Migration to the nerve tissue will 
result in the characteristic pathology of paralytic poliomyelitis. Cell lysis 
takes place approximately 6-10 hours after infection fig (1.3). The whole life 
cycle of poliomyelitis is depicted in fig (1.3). 
1.8 Epidemiology 
1.8.1 Virus transmission 
Poliomyelitis is highly contagious and spreads easily by human-to-human 
contact In endemic areas (Kew etal., 2005). Wild polioviruses can infect 
virtually the entire human population (Parker, 1998). It is seasonal in 
temperate climates, with peak transmission occurring in summer and autumn 
(Kew etal., 2005). These seasonal differences are far less pronounced in 
tropical areas (Kew etal., 2005). The time between first exposure and first 
symptoms is usually 6 to 20 days, with a maximum range of 3 to 35 days 
(Racaniello, 2006).Virus particles are excreted in the feces for several weeks 
following initial infection (Racaniello, 2006). The disease is transmitted 
primarily via the fecal-oral route, by ingesting contaminated food or water. It 
is occasionally transmitted via the oral-oral route (ohri, 1999), a mode 
especially visible in areas with good sanitation and hygiene (Kew etal., 
2005).Polio is most infectious between 7–10 days before and 7–10 days after 
the appearance of symptoms, but transmission is possible as long as the virus 
remains in the saliva or feces(ohri, 1999). 
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1.8.1.1 Fecal-oral polio transmission  
       Polio transmission most often occurs through contact with stool from an 
infected person. This spread of poliovirus can happen in one of several 
ways, which include eating food or drinking liquids that are contaminated 
with poliovirus, touching contaminated surfaces or objects for example, 
when changing diapers, and then placing the contaminated hand in the 
mouth and sharing food or eating utensils with someone infected with 
poliovirus. 
1.8.1.2 Oral-oral polio transmission  
Less commonly, polio transmission occurs through contact with 
respiratory droplets or saliva. When an infected person sneezes or coughs, 
droplets spray into the air. The infected mucus or saliva can land in other 
people's noses or throats when they breathe or put their fingers in their 
mouth, nose, or eyes after touching an infected surface. 
1.4 Pathophysiology  
       Poliovirus enters the body through the mouth, infecting the first cells it 
comes in contact with which is the pharynx (throat) and intestinal mucosa. It 
gains entry by binding to an immunoglobulin-like receptor, known as the 
poliovirus receptor or CD155, on the cell surface. (He etal., 2003). The virus 
then hijacks the host cell's own machinery, and begins to replicate. 
Poliovirus divides within gastrointestinal cells for about a week, from where 
it spreads to the tonsils (specifically the follicular dendritic cells residing 
within the tonsilar germinal centers), the intestinal lymphoid tissue including 
the M cells of Payer’s patches, and the deep cervical and mesenteric lymph 
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nodes, where it multiplies abundantly. The virus is subsequently absorbed 
into the bloodstream (Yin & Almond, 1996).  
     Poliovirus can survive and multiply within the blood and lymphatics for 
long periods of time, sometimes as long as 17 weeks (Todar, 2006).  In a 
small percentage of cases, it can spread and replicate in other sites such as 
brown fat, the reticuloendothelial tissues, and muscle (Sabin, 1956), this 
sustained replication causes a major viremia, and leads to the development 
of minor influenza-like symptoms. Rarely, this may progress and the virus 
may invade the central nervous system, provoking a local inflammatory 
response. In most cases this causes a self-limiting inflammation of the 
meningitis, which is known as non-paralytic aseptic meningitis (Chamberlin 
& Narins ,  2005) Penetration of the CNS provides no known benefit to the 
virus, and is quite possibly an incidental deviation of a normal 
gastrointestinal infection(Mueller etal., 2005) . The mechanism by which 
poliovirus spreads to the CNS is poorly understood, but it appears to be 
primarily a chance event largely independent of the age, gender, or 
socioeconomic position of the individual (Mueller etal., 2005).   
 1.10 Types of poliomyelitis and clinical spectrum of the disease 
 1.10.1 Subclinical infection: In apparent subclinical infection accounts for 
(90 - 95%) of the majority of poliovirus infections.  
1.10.2 Abortive infection: This group of patients account for (4 - 8%) only 
suffers the minor illness which comprises of influenza-like symptoms such 
as fever, malaise, drowsiness, headache, nausea, vomiting, constipation and 
sore throat. Recovery occurs within a few days and the diagnosis can only 
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be made by the laboratory. The minor illness may be accompanied by 
aseptic meningitis which is similar to the meningitis caused by other 
enteroviruses and usually resolve without sequelae within 2 - 10 days.  
1.10.3 Major illness: Accounts for (1 - 2%).the major illness may present 2 
- 3 days following the minor illness. In most cases though, the major illness 
occur without evidence of any preceding minor illness. Signs of aseptic 
meningitis are common. Involvement of the anterior horn cells lead to 
flaccid paralysis. Painful muscle spasms and in coordination of non-
paralyzed muscles may occur. Involvement of the medulla may lead to 
respiratory paralysis and death. The paralysis usually develops over several 
days and some recovery may take place. Any effects persisting for more 
than 6 months are usually permanent. This is known as paralytic 
poliomyelitis.  
1.10.3.1 Paralytic poliomyelitis  
             In around 1% of infections, poliovirus spreads along certain nerve 
fiber pathways, preferentially replicating in and destroying motor neurons 
within the spinal cord, brain stem, or motor cortex. This leads to the 
development of paralytic poliomyelitis, the various forms of which (spinal 
bulbar and bulb spinal) vary only with the amount of neuronal damage and 
inflammation that occurs, and the region of the CNS that is affected. 
       The destruction of neuronal cells produces lesions within the spinal 
ganglia; these may also occur in the reticular formation, vestibular nuclei, 
cerebellar vermis, and deep cerebellar nuclei(Mueller etal, 2005). 
Inflammation associated with nerve cell destruction often alters the color 
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and appearance of the gray matter in the spinal column, causing it to appear 
reddish and swollen (Chamberlin &Narins,2005 ).Other destructive changes 
associated with paralytic disease occur in the forebrain region, specifically 
the hypothalamus and thalamus (Mueller etal , 2005).The molecular 
mechanisms by which poliovirus causes paralytic disease are poorly 
understood. Early symptoms of paralytic polio include high fever, headache, 
stiffness in the back and neck, asymmetrical weakness of various muscles, 
sensitivity to touch, difficulty swallowing, muscle pain, loss of superficial 
and deep reflexes, paresthesia , irritability, constipation, or difficulty 
urinating. Paralysis generally develops one to ten days after early symptoms 
begin, progresses for two to three days, and is usually complete by the time 
the fever breaks (Silverstein et al., 2001).The likelihood of developing 
paralytic polio increases with age, as does the extent of paralysis. In 
children, non-paralytic meningitis is the most likely consequence of CNS 
involvement, and paralysis occurs in only 1 in 1000 cases. In adults, 
paralysis occurs in 1 in 75 cases (Gawne and Halstead, 1995). In children 
under five years of age, paralysis of one leg is most common; in adults, 
extensive paralysis of the chest and abdomen also affecting all four limbs 
quadriplegia is more likely (Young, 1989). Paralysis rates also vary 
depending on the serotype of the infecting poliovirus; the highest rates of 
paralysis (1 in 200) are associated with poliovirus type 1, the lowest rates (1 
in 2,000) are associated with type 2 (Nathanson and Martin ,1979).  
1.10.3.2 Spinal poliomyelitis 
 Is the most common form of paralytic poliomyelitis; it results from 
viral invasion of the motor neurons of the anterior horn cells, or the ventral  
gray matter section in the spinal column, which are responsible for 
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movement of the muscles, including those of the trunk, limbs and the 
intercostal muscles (Frauenthal & Manning , 1914).Virus invasion causes 
inflammation of the nerve cells, leading to damage or destruction of motor 
neuron ganglia. When spinal neurons die, wallerian degeneration takes 
place, leading to weakness of those muscles formerly innervated by the now 
dead neurons (Cono & Alexander, 2002).With the destruction of nerve cells, 
the muscles no longer receive signals from the brain or spinal cord; and 
without nerve stimulation, the muscles atrophy, becoming weak, floppy and 
poorly controlled, and finally completely paralyzed (Frauenthal & Manning, 
1914). Progression to maximum paralysis is rapid (two to four days), and is 
usually associated with fever and muscle pain (Cono & Alexander, 2002). 
Deep tendon reflexes are also affected, and are usually absent or diminished 
sensation in the paralyzed limbs (Cono & Alexander ,2002).The extent of 
spinal paralysis depends on the region of the cord affected, which may be 
cervical, thoracic, or lumbar . The virus may affect muscles on both sides of 
the body, but more often the paralysis is asymmetrical(Yin & Almond 
,1996).Any limb or combination of limbs may be affected—one leg, one 
arm, or both legs and both arms. Paralysis is often more severe proximally 
than distally (Yin & Almond, 1996). 
1.10.3.3 Bulbar poliomyelitis 
 Comprising about 2% of cases of paralytic poliomyelitis. Bulbar 
poliomyelitis occurs when poliovirus invades and destroys nerves within the 
bulbar region of the brain stem (Atkinson et al., 2007). The destruction of 
these nerves weakens the muscles supplied by the cranial nerves, producing 
symptoms of encephalitis, and causes difficulty breathing, speaking and 
swallowing (Leboeuf, 1992).Critical nerves affected are the gloss 
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pharyngeal nerve, which partially controls swallowing and functions in the 
throat, tongue movement and taste; the vagus nerve, which sends signals to 
the heart, intestines, and lungs; and the accessory nerve, which controls 
upper neck movement. Due to the effect on swallowing, secretions of mucus 
may build up in the airway causing suffocation (Silverstein etal., 2001). 
Other signs and symptoms include facial weakness, caused by destruction of 
the trigeminal nerve and facial nerve, which innervate the cheeks, tear ducts, 
gums, and muscles of the face, among other structures; double; difficulty in 
chewing; and abnormal respiratory rate, depth, and rhythm, which may lead 
to respiratory arrest. Pulmonary edema and shock are also possible, and may 
be fatal.  
1.10.3.4 Bulb spinal poliomyelitis 
             Approximately 19% of all paralytic polio cases have both bulbar and 
spinal symptoms; this subtype is called respiratory poliomyelitis or bulb 
spinal poliomyelitis (Atkinson etal., 2007). Here the virus affects the upper 
part of the cervical spinal cord and paralysis of the diaphragm occurs. The 
critical nerves affected are the phrenic nerve, which drives the diaphragm to 
inflate the lungs, and those that drive the muscles needed for swallowing. By 
destroying these nerves this form of polio affects breathing, making it 
difficult or impossible for the patient to breathe without the support of a 
ventilator. It can lead to paralysis of the arms and legs and may also affect 
swallowing and heart functions. 
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1.11 Immunity against poliovirus                                                                                      
       Humoral Immunity has two components which are systemic humoral 
and local gastrointestinal (GI) mucosal immunity; they are of benefit against 
poliomyelitis (Ghendon and Robertson, 1994). Humoral systemic immunity 
is serum mediated immunity; IgG is the most important and long-lasting 
serum antibody against poliovirus. Even in the absence of mucosal 
immunity, serum IgG antibody can fully protect the individual from 
paralytic poliomyelitis by neutralizing virus that reaches the blood, thus 
preventing central nervous system penetration, where's Person-to-person 
transmission of poliovirus is primarily prevented by local GI mucosal IgA 
antibody, which prevents replication and shedding of poliovirus from the 
pharynx and intestine. Neither natural infection nor vaccination with either 
available vaccine produces mucosal immunity in all exposed individuals. 
Those with protective levels of serum IgG can still replicate and shed 
poliovirus from the nasopharynx and intestine in the absence of mucosal 
immunity. Such individuals may therefore transmit poliovirus infection to 
susceptible contacts.  
1.12 Laboratory diagnosis  
1.12.1 Virus isolation                                                                                
         Faeces - faeces is the preferred specimen as polioviruses multiply in 
the gastrointestinal tract for several weeks after infection (WHO, 1997). 
Faecal samples of approximately 4-8g should be collected within 14 days 
(preferably 7 days) of illness onset and placed in a dry, clean, leak proof 
container with a screw cap. Isolation rates are increased by obtaining 2 
samples 24-48 hrs apart. If it is impossible to obtain faeces a rectal swab 
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may be substituted, but the small quantity of faecal material thus obtained is 
inadequate for routine use. After collection faeces should be immediately 
placed at 4˚C and shipped to the laboratory at this temperature within 72 hrs 
of collection. If this is not possible the specimen must be frozen, preferably 
at -70˚C (-20˚C is adequate), and transported to the laboratory frozen, 
preferably on dry ice.  
Throat swab are inferior to faeces as the titer of virus is 10 fold lower 
and the duration of shedding is short (7-10 days) but they are not 
recommended for poliovirus surveillance by WHO. If swabs are employed 
they should be cotton, rayon or dacron-tipped, plastic coated or aluminum 
shafted. Once the swab is taken it should be placed into viral transport 
medium and transported to the laboratory at 4˚C. In the CSF, polioviruses 
are rarely detected by culture which is therefore also not recommended for 
poliovirus surveillance by WHO. If the CSF is collected a minimum of 0.5 
ml should be placed into a sterile, leak proof tube, chilled at 4˚C and 
transported immediately to the laboratory. 
       Biopsies and post mortem specimens - In fatal cases neurological tissue 
of approximately 1cm3, preferably from cervical and lumbar cord, medulla 
and pons, should be obtained aseptically and placed in separate sterile 
containers with sufficient viral transport medium to keep the specimens 
moist. Also a segment of descending colon 3-5cm long, containing faecal 
material should be taken. 
1.12.2 Serological diagnosis 
       The serological diagnosis of poliovirus infection in patients with 
poliomyelitis is not recommended due to difficulties in interpreting results in 
 23
the context of high coverage with polio vaccine. Also serology cannot 
distinguish antibody to wild-type poliovirus from antibody to a vaccine 
strain (Sabin), but serology is used for determination of immunity to 
poliovirus. A standard microneutralization procedure is employed using 100 
TCD50 of vaccine (Sabin) strains of poliovirus 1, 2 and 3 as challenge 
viruses grown in HEp-2 cells, and doubling dilutions of patient sera from a 
starting dilution of 1/8.The neutralization end point is calculated by the 
Karber formula and is expressed as international units by comparison with 
the International Standard Poliovirus Antiserum, National Institute for 
Biological Standards and Control, UK (NIBSC). 
 A single blood sample is required for determination of immunity in 
serum of minimum 0.5ml volume; preferably 2ml. Serum should be 
transported to the laboratory at 4˚C within 72hrs of collection, or frozen and 
transported frozen. 
1.12.3 Molecular diagnosis  
1.12.3.1 PCR technique 
The enteroviruses, including polioviruses, coxsackie viruses, 
echoviruses, and the more recently classified enteroviruses are among the 
most common and important of the human viral pathogens (Melnick, 1990). 
Acute flaccid paralysis surveillance and laboratory diagnosis of 
poliomyelitis is a critical part of the World Health Organization’s initiative 
for poliomyelitis eradication by the year 2000 and it is thus necessary that 
rapid and reliable techniques be available for differentiating between 
polioviruses and non-polio enteroviruses. (WHO, 1988). 
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Diagnosis of enterovirus infection still relies largely on cell culture 
techniques, with subsequent typing of the enteroviruses by neutralization 
techniques which are both lengthy and expensive (Lennette, 1992), (Lim & 
Melnick,1969).Differentiation between polioviruses and nonpolio 
enteroviruses by microneutralization or immunofluorescence with 
poliovirus-specific antisera is less expensive but is still time-consuming. 
Recently, mouse L cells transfected with the poliovirus receptor have been 
developed for the selective isolation of polioviruses and the exclusion of 
other enteroviruses (Hovi & Stenvik, 1994., Pipkin etal., 1993). 
PCR techniques for the detection of enteroviruses in clinical 
specimens and infected tissue culture supernatants have been well 
established (Chapman etal., (1990), Hovi & Stenvik, (1994). However, the 
identification of polioviruses by these techniques requires subsequent 
hybridization with poliovirus-specific probes (Chapman etal., 1990) or 
restriction enzyme analysis (Ka¨mmerer etal., 1994). 
PCR primers specific for polioviruses have been described, but they 
are not able to detect all poliovirus strains (Abraham etal, 1993), or several 
combinations of primer pairs need to be used simultaneously in order to 
obtain positive results (Egger etal, 1995). The assay is sensitive (4 PFU) and 
highly specific for polioviruses. By this technique it is possible to identify 
polioviruses, to differentiate them from other enteroviruses within 24 h, and 
to determine the genotypes of wild-type polioviruses by direct sequencing of 
the PCR products. 
1.12.3.2 Hybridization technique    
Detection of various viral RNAs by molecular hybridization with 
radio labeled cDNA or cRNA probes has been reported. A sensitive and 
specific test for the detection of enteroviruses was developed by using sub- 
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genomic cRNA transcripts of poliovirus type 1 synthesized in vitro and 
designated as riboprobes. The riboprobe corresponding to the 5'-noncoding 
region is a probe that hybridizes with the majority of enteroviruses but not 
with other DNA or RNA viruses or bacteria, and hence, it is specific for 
enteroviruses. The VP1 riboprobe is a transcript of the part of the sequence 
that codes for capsid protein VP1; it hybridizes specifically with all three 
serotypes of polioviruses and, to a lesser extent, with some coxsackie viruses 
type A and echovirus type 7. This probe can be considered a specific probe 
for discriminating between polioviruses and other enteroviruses in 
epidemiologic studies. 
1.13 Immunity against Poliomyelitis virus Vaccines  
Poliomyelitis cannot be cured once an infection has occurred, but the 
symptoms can be treated while the virus runs its course of infection. Because 
poliomyelitis cannot be cured, vaccination is the only way to avoid the 
paralytic risks presented by infection. Two polio vaccines exist: inactivated 
polio vaccine (IPV) and oral polio vaccine (OPV). Both vaccines contain 
constituents of all three types of poliovirus as well as trace amounts of 
antibiotics like streptomycin and polymycin (WHO, 2003).  
1.14 Oral polio vaccine 
The Oral Polio Vaccine (OPV) was developed in 1958 by Sabin who 
attenuated the wild type poliovirus by passaging the virus in monkey kidney 
epithelial cells. The commonly used form of the oral polio vaccine is 
trivalent, which means that it contains live attenuated strains of the three 
serotypes of poliovirus. Trivalent OPV is characterized in vivo by efficient 
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growth properties in the intestinal tract, unaltered immunogenic properties 
with respect to wild type progenitors, and attenuated neurovirulence after 
experimental intraspinal injection into primates. This means that an 
individual immunized with trivalent OPV induces long-lasting (frequently 
life long) protective immunity of the gastrointestinal tract to all known forms 
of poliovirus. 
Most early trivalent preparations of OPV contained the three 
poliovirus types in equal proportions; however, in 1961 a study in Canada 
evaluated a “balanced” formulation of trivalent OPV which contained 106, 
105, and 105.5 TCID50 of Sabin types 1, 2, and 3, respectively (Robertson , 
1962). Whereas there had been relatively lower seroconversion rates to types 
1 and 3 when administered in equal proportion, the “balanced” preparation 
resulted in detectable levels of neutralizing antibody against all three types 
in almost all subjects. The “balanced” formulation was adopted in Canada in 
1962 and a similar formulation was adopted in the USA in 1963 since 
studies of monovalent preparations in developing countries had shown 
serological responses in children similar to those seen in industrialized 
countries, the “balanced” trivalent formulation was adopted for use in 
developing countries without further testing. 
1.14.1 Humoral Immunity to OPV 
1.14.1.1 Mucosal Immunity to OPV 
          The immune response to OPV closely parallels that to natural 
infection. Virus multiplies in the same alimentary tract sites and in related 
lymphoid tissues and is excreted in the feces for several weeks and, usually 
after large doses, in pharyngeal secretions for up to 10 to 12 days (Fox 
1984). 
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  The administration of OPV results in the development of secretory 
IgA antibody in the nasopharynx and intestine approximately one to three 
weeks after immunization. Secretory antibody activity has been observed to 
persist for as long as 5 to 6 years (Ogra, 1984). 
 Local secretory IgA antibody induced by OPV is considered to be 
important in protecting the individual and in reducing the rate of 
transmission of wild type polioviruses by immunized persons. Colostrum 
produced in the first three days after childbirth contains secretory IgA 
antibody, which might interfere with the immune response to OPV. 
Nevertheless, several studies show that among breastfed infants who are fed 
OPV in the first three days of life, 20% to 40% develop serum antibodies 
and 30% to 60% excrete vaccine virus (Halsey and Galazka, 1985).  
Colonization enables the production of secretory IgA, which serves as 
an important defense against naturally acquired poliovirus, as well as smaller 
amounts of IgM and IgG. Since it is a polymer, secretory IgA can cross-link 
large antigens with multiple epitopes at mucous membrane surfaces, which 
are the main entry sites for most pathogenic organisms. The binding of IgA 
to viral surface antigens prevents the attachment of the pathogen to the 
mucosal cells, thereby inhibiting viral infection of the cells. Complexes of 
secretory IgA and antigen are entrapped and eliminated by the ciliated 
epithelial cells of the respiratory tract or by the peristalsis of the gut. 
Since the three attenuated strains of poliovirus present in the OPV 
interfere with each other's replication in the intestine, boosters of OPV are 
required to induce protective immunity to all three polio serotypes. In the 
first immunization, one strain will grow most effectively, and immunity to 
this strain will be induced. With the second immunization, the immune 
response generated to the first strain will inhibit the growth of that same 
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strain, such that a second strain will replicate most successfully, inducing 
immunity to the second strain. Similarly, immunity is induced to the third 
strain with the third booster (Miller etal., 1996). 
1.14.2 Systemic humoral immunity to OPV 
1.14.2.1 Serum antibodies 
          During the 1970s less-than-optimal responses to trivalent OPV in 
developing countries became apparent when reports of low rates of 
seroconversion to poliovirus types 1 and 3 began to appear in the medical 
literature (Ghosh etal., 1970, John & Jayabal 1972, and Oduntan etal., 
1978). 
A recent review examines data accumulated in developing countries 
during the past 25 years (Patriarca etal., 1991). Thirty-two studies in 15 
developing countries reported the response of at least 20 children to three 
doses of trivalent Sabin-derived OPV which contained at least 106, 105, and 
105.5 TCID50 of types 1, 2, and 3 poliovirus respectively. After three doses 
of trivalent OPV, there was wide variation in the percentage of children 
seroconverting with rates of 73% (range 36% to 99%) for type 1, 90% 
(range 71% to 100%) for type 2, and 70% (range 40% to 99%) for type 3. 
  The interval between doses may be important, in view of prolonged 
excretion of vaccine virus and the potential for interference with response to 
subsequent doses. Continuing intestinal infection (manifested by fecal 
excretion of one strain of OPV) could potentially interfere with the immune 
response to a subsequent dose. These and other factors which may influence 
the serological response of children in developing countries to OPV are now 
under study in WHO-sponsored prospective clinical trials in different parts 
of the world. 
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1.14.2.2 Persistence of serum antibodies to OPV 
          Duration of immunity is best examined in long term prospective 
studies in which children who have received vaccine of known potency are 
followed for a number of years post immunization. So far, few prospective 
studies have been conducted. 
In the United States 57 infants received 3 doses of trivalent OPV in 
1968 and all had titers of 10 or higher for all 3 types at that time. Serum 
obtained from these children 5 years later showed the proportion with 
neutralizing antibodies at a titer 2 or higher was 98% for type 1 poliovirus, 
98% for type 2, and 84% for type 3. A second group of 58 children received 
4 doses of trivalent OPV in 1968 and all had antibody at a titer of 10 or 
higher for all three types. Five years later the proportion with neutralizing 
antibodies at a titer of 2 or higher was 98%, 98%, and 87% for types 1, 2, 
and 3, respectively. All sera from this study that were negative with the 
standard microneutralization technique were tested again with a more 
sensitive plaque reduction method. Four of 5 sera samples without type 1 
antibody on the microneutralization test demonstrated antibody on the 
plaque reduction test. Two sera samples negative for type 2 antibodies and 
15 of 17 sera samples negative for type 3 antibodies by the neutralization 
method were positive by plaque reduction (Krugman et al., 1977). 
In Italy a group of 276 children were followed for 4 years after receipt 
of 3 doses of trivalent OPV. More than 94% maintained neutralizing 
antibody titers of 4 or higher against type 1 and type 2; however, only 84% 
and 75% had type 3. 
Data from a prospective study conducted in Japan suggest that during the 5 
years after two doses of trivalent OPV (at 3 and 6 months of age), 
neutralizing antibody titers for types 1 and 2 decline gradually, whereas a 
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more rapid drop and statistically significant is seen with type 3 (Nishio et al., 
1984). The same study found similar results in a group of children who 
received a booster dose of OPV at 5 years of age and were followed 
annually for the next 4 years. 
Prospective data on persistence of antibody in the developing 
countries is lacking. Given the lesser serological response in some countries, 
it will be important to assess antibody persistence in these settings in the 
future. 
1.15 Advantages of OPV 
          There are many biological and practical advantages to the Oral Polio 
Vaccine. Since attenuated vaccines are capable of transient growth, the OPV 
allows prolonged exposure of the immune system to the epitopes on the 
attenuated organisms, resulting in increased immunogenicity and memory-
cell development. OPV also indirectly protects other susceptible individuals 
by secondary vaccination, which means that vaccinated individuals may 
spread the vaccine virus in the community and thereby inhibit the spread of 
the wild type virus if it occurs in the population (Herd immunity). 
Significantly, OPV prevents the vaccine from acting as a carrier of wild type 
poliovirus, and as stated, confers long-lasting immunity. The OPV is also 
easily administered by giving children a sugar cube or sugar liquid 
containing the vaccine, neither of which requires extensive medical training 
to be administered. 
1.16 Disadvantages of OPV 
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          The most serious disadvantage of the Oral Polio Vaccine is the risk of 
vaccine-associated paralytic polio as a result of the vaccination. In fact, in 
any attenuated vaccine, there exists a danger that the attenuated form will 
revert to the virulent form. The Centers for Disease Control estimate that 1 
case per 2.5 million doses of OPV distributed results in vaccine-associated 
paralytic polio, however, the risk increases significantly for the first dose of 
OPV, which results in 1 case per 790,000 doses administered. The risk is 
even higher for children receiving their first dose of OPV, as 1 in 520,000. 
Children acquire vaccine-related polio after receiving their first OPV dose. 
Particularly problematic in Third World countries, other gastrointestinal 
viruses interfere with the replication of the attenuated polio vaccine viruses 
in the intestine of the vaccines. Also, the fact that several boosters are 
required to induce protective immunity significantly decreases the success of 
polio vaccination programs, which is cooperated by studies that reveal that 
in Third World countries 20% of people, fail to return for each subsequent 
booster. In the U.S.A public health campaign is currently underway to 
minimize the risk of vaccine-related polio by adhering to a specific CDC-
recommended immunization schedule: 2 doses of IPV followed by 2 doses 
of OPV as part of the routine childhood immunization schedule. If the 
Inactivated polio vaccine, which has no known risk of vaccine-associated 
polio, is administered prior to the Oral Polio Vaccine, then the killed vaccine 
prevents against the small risk of contracting polio from the live vaccine. 
This immunization schedule is expected to reduce the rate of vaccine-
associated paralytic polio in the USA by 50 to 75% without creating a risk of 
paralytic polio caused by naturally circulating virus. Unfortunately, the 
relative expense of IPV as compared with OPV inhibits the implementation 
of this immunization schedule in certain countries. Immunosuppressed 
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individuals should not take the Oral Polio Vaccine, and should avoid contact 
with persons who have received the Sabin vaccine for two weeks post 
vaccination. This includes people with AIDS, other immunodeficiency 
diseases, cancer, leukemia, and lymphoma. People receiving radiation 
treatments, medications to treat cancer, corticosteroids, or other 
immunosuppressive medications should also follow these recommendations. 
Those individuals should be vaccinated with IPV. 
1.17 Inactivated Polio Vaccine 
          Enders et al., (1949) described the successful cultivation of the 
Lansing strain of poliovirus in cultures of non-nervous human tissues.This 
was the break that allowed development of polio vaccines.The first 
inactivated polio vaccine (IPV) was produced by Salk using virus grown on 
monkey kidney cells and inactivated with: formalin. After extensive field 
testing, IPV was licensed in the United States in 1955.The strains of virus 
used in the vaccine were Mahoney (type l), MEF-I (type 2) and Saukett 
(type 3). The same strains: are used by all manufacturers of IPV today, 
except in Sweden where the Brunenders strain is used for type 1 (Salk & 
Drucker, 1988). 
IPV is standardized in D antigen units.The D antigen content of IPV is 
measured in vitro by ELISA or by a double immunodiffusion assay. These 
tests need to be correlated with an in vivo system, usually in rats or chickens 
(Minor, 1990). The original IPV contained 20, 2, and 4 D antigen units of 
poliovirus types 1, 2, and 3, respectively, although the potency varied 
considerably. In 1978 the Rijks Institute in Holland introduced a new culture 
technique using cells on microcarriers to produce a more potent IPV 
containing 40, 8, and 32 D antigen units of types 1, 2, and 3, respectively 
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(Van etal., 1984). Vaccine of this potency is known as enhanced potency 
IPV, or eIPV. DPT vaccine has been combined with eIPV with good 
serological response to both vaccines and the convenience of a single 
injection. 
1.17.1 Humoral immunity to IPV 
          IPV produces protective antibodies in the blood (serum immunity). 
After 2 doses of enhanced-potency IPV, high levels of serum-neutralizing 
antibodies to all 3 types of poliovirus appears in 94-100% of individuals, and 
after 3 doses, seroconversion appears in 99-100% of individuals. This serum 
immunity prevents the spread of the virus to the CNS and provides 
protection against polio paralysis. The suggested immunity is prolonged and 
perhaps lifelong and circulating antibodies have persisted for at least 10 
years as shown in field studies in Europe. However, IPV induces only low 
levels of immunity to poliovirus in the gut. Enhanced-potency IPV induces 
mucosal immunity by inhibiting pharyngeal acquisition of poliovirus and, to 
a lesser extent, intestinal acquisition, yet the extent of mucosal immunity 
induced by IPV is far less than OPV. Therefore, while OPV can prevent the 
spread of wild poliovirus, IPV is a less reliable vaccine. However, even 
though this vaccine does not induce much secretory IgA in the alimentary 
tract, its effectiveness has been demonstrated in Sweden, Finland, Iceland, 
Holland, Norway and Canada where the exclusive use of IPV has been 
adopted (Miller et al., 1996).   
1.18 Advantages of IPV 
          The virus is not live, thus it is easier to manage than OPV and there is 
no risk of vaccine-associated polio paralysis (VAPP).Immunization triggers 
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an excellent immune response and long-lasting immunity to all 3 poliovirus 
types and no serious adverse effects to date exist 
1.19 Disadvantages of IPV  
           IPV induces only little immunity in intestinal tract; if an individual is 
infected with the wild-type poliovirus, the virus can multiply in the 
intestines and be shed in stools, ultimately heightening the risk of viral 
circulation within the community more over the cost of IPV is over 5 times 
that of OPV and the administering of IPV requires trained health workers, in 
addition   IPV requires additional injections in infants until new combination 
products are available. A person is considered to be fully immunized if he or 
she has received a primary series of at least three doses of inactivated 
poliovirus vaccine (IPV), three doses of live oral poliovirus (OPV), or four 
doses of any combination of IPV and OPV. To eliminate the risk of vaccine-
associated paralytic poliomyelitis, OPV has not been recommended for 
routine immunization in the United States since January 2000, and 
poliomyelitis is no longer available in this country. OPV continues to be 
used in the majority of countries and for global polio eradication activities. 
1.20 New strategies for eradication of poliomyelitis  
          As the target year for the eradication of poliomyelitis approaches, the 
objectives of the World Health Organization is working to implement 
improved methods for identifying wild-type poliovirus and determining 
infection with poliovirus including:   
1. Polymerase Chain Reaction to identify wild-type poliovirus in clinical 
specimens and environmental samples.  
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2. Nucleic acid hybridization to specifically identify all wild-type 
polioviruses.  
3.  Using of restriction fragments length polymorphism (RFLP).  
4. Use of mouse cell lines expressing the human poliovirus receptor.  
5. Use of Sabin-specific monoclonal antibodies for rapid identification of 
Sabin-related poliovirus by neutralization.  
6. Development of a standard test for detection of poliovirus-specific IgM 
antibodies to evaluate transgenic mice as an animal model for 
neurovirulence test of oral poliomyelitis vaccine. Current objectives 
guiding vaccine research and development include defining more 
efficient immunization strategies and new delivery systems. Improving 
immunization strategies means investigating approaches such as nucleic 
acid vaccines, combined vaccines, mucosal immunization, and neonatal 
vaccination. There is a major effort in polio research particularly to 
produce a DNA vaccine, in which genes from polio would be inserted 
into a bacterial plasmid. DNA vaccines successfully elicit an immune 
response, although the mechanism of this response is as yet 
undetermined. A potential risk of using DNA vaccines in humans is that 
injecting naked DNA might not be safe; this foreign DNA could insert 
itself into and damage human chromosomes and potentially increase the 
risk of cancers or autoimmune disorders. As stated, multiple boosters of 
vaccine are required to induce immunological memory to all three 
serotypes of poliovirus. Ideally, children could receive a single vaccine to 
replace the current childhood immunization schedule; however, because 
of the antagonistic effects of various vaccines, this is not yet possible. 
Efforts are however underway to minimize the number of boosters 
required for polio immunization, and include research into the 
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development of a single vaccine with a time-release mechanism. Other 
possibilities to increase the efficiency of polio vaccination include using 
adjuvant, particularly to improve the mucosal immune response typically 
generated by OPV. Also, a vaccine that induced only a localized immune 
response would minimize tissue damage generated by processes such as 
innocent bystander lysis 
1.21 Eradication of poliomyelitis in Sudan 
       As part of the global initiative to eradicate polio, the Federal Ministry of 
Health of the Government of Sudan, in collaboration with the World Health 
Organization conducted 5 rounds of a national polio immunization campaign 
in 2007 and 1 sub-national immunization round. The campaign’s coverage 
results in 2007 showed that 8,910,641 children under the age of 5 years 
giving around 99% of the targeted population were vaccinated across 
Sudan. . The country was free from the endemic polio virus from April 2001 
until May 2004 when a case of poliovirus imported from neighboring Chad 
led to an outbreak. The outbreak spread and resulted in 155 cases, ending in 
June 2005. No other case was reported in the period up to the end of 
December 2007,however, paralysis was reported in a 22 month old an 
Ethiopian female child from Korchar seen in Akobo in Jonglei State seeking 
medical care on 6 march 2008. The case was reported by Akobo AFP 
surveillance team and two adequate stool samples were collected and sent to 
KEMRI laboratory for analysis. The primary culture showed poliovirus P1. 
The isolates were sent to a South African (SA) reference laboratory for 
intratypic differentiation (ITD) testing. On April 2008, the SA laboratory 
confirmed the presence of wild poliovirus P1, which is 96% close to 
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poliovirus confirmed in Sudan in 2004. Last Eradication campaigns in 
Sudan were started in the 25th of August 2008 covering Khartoum and other 
states of Sudan. 
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Chapter two 
Materials and methods 
2. Area of the study                                             
This study was carried out in Omdurman municipality hospitals 
during the period of February 2007 to February 2008 to study the prevalence 
of poliomyelitis virus antibodies in saliva and sera of OPV immunized 
preschool- aged children one to five years old. 
2.1 Collection of data 
Data concerning history of immunization against poliomyelitis, and 
other medical information and demographic data were collected using 
structured questionnaire with informed consent of the mother of each 
participant .The questionnaire is attached as appendix. The study population 
was divided into groups according to age, sex and area of residence. The age 
group includes: group (1) less than two years old, group (2) 3-4 years old, 
and group (3) more than 4 years old. The area of residence was divided into 
5 areas: North, East North, South, West and old Omdurman.  
2.1.1 Collection of serum 
            Random blood samples 3-5ml were collected in sterile plain 
international containers, under supervision of trained nurses from 100 
preschool aged child from different areas of Omdurman municipality. Blood 
samples were kept in inclined position for four hours, and then left at 40C 
overnight. On the next day sera were separated, labeled and kept at -200C. 
2.1.2 Collection of saliva 
From the same children 100 sample of saliva 1-2ml was collected in 
sterile bottles, labeled and stored at -200C. 
2.2 Preparation of buffers and solutions 
2.2.1 Coating buffer 
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       Carbonate- bicarbonate buffer is coating buffer of pH 9.6 that prepared 
by addition of  1.59g of Na2CO3 and 2.93 g of NaHCO3 to 1 liter of distilled 
water.  
2.2.2 Washing buffer 
0.15M Phosphate buffered saline (PBS), pH7.2 was prepared by 
dissolving 8.00g sodium chloride NaCl, 0.20g potassium chloride KCl, 
1.15g Disodium hydrogen phosphate Na2HPO4 and 0.20g potassium 
Dihydrogen phosphate (KH2PO4) in one liter of distilled water and the PH 
was adjusted. 
     2.2.3 Blocking solution 
It was prepared as 2% bovine serum albumin (BSA) in PBS. 
 2.2.4 Diluent buffer 
The diluent that used for sample dilution was PBS containing 0.5% 
BSA and 0.05%Tween 80 (PBS-Tween80).   
2.2.5 Stop solution 
1N HCl was used for stopping the enzymatic reaction. 85.85ml of 
36% HCL was completed to one liter by adding distilled water to give a 
volume of 1N HCl. 
2.2.6 The chromagen Substrate 
The substrate O-Phenylene diamine dihydrochloride OPD (Sigma 
cat#p8412) was used. The 30mg substrate tablet was dissolved in 75ml 
0.05M Phosphate-citrate buffer, pH 5.0 to give a concentration of 0.40mg/ml 
as recommended by the manufacture. 40 µl of fresh 30% hydrogen peroxide 
per 100ml of substrate buffer solution was added immediately prior to use. 
2.3 Indirect-house ELISA for the detection of poliovirus antibodies 
2.3.1 Poliovirus specific salivary IgA ELISA 
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The hundred saliva samples kept at -200C were allowed to reach room 
temperature before tested for the presence of poliovirus specific SIgA Abs. 
2.3.2 Preparation of poliovirus antigen 
Oral poliovirus vaccine was obtained from the expanded 
immunization programme in the Federal Ministry of Health, Khartoum. The 
vaccine was produced by Chiron vaccine-PolioralTM .It was supplied in 2ml 
tubes containing the three poliovirus serotypes. The OPV was heat 
inactivated for 30minutes at 650C. Each vaccine tube was diluted in 
carbonate buffer to give a final concentration of 106 pfu/ml.This 
concentration of poliovirus Ag was used for coating microtiter plates. 
2.3.3 Preparation of positive and negative control for saliva SIgA 
Three saliva samples were selected from non vaccinated individuals, 
and included as negative control, and their low absorbance values were 
confirmed in pilot ELISA screening test. Likewise, three saliva samples 
from multivaccinated children were selected as positive control, and their 
high absorbance values confirmed by pilot ELISA screening test. 
2.3.4 IgA enzyme conjugate 
Goat anti-Fc human IgA conjugated horse radish peroxidase was 
obtained from Nordic Tilburg Holland code GAHu/IgA Fc/po.The conjugate 
was reconstituted by adding 1ml sterile distilled water to give a final dilution 
of 1/1000.This was further distributed in0.1ml volume in eppendorff tubes 
and kept at -200C. For performing the ELISA 1/10000 dilution was prepared 
by adding 9.90ml dilution buffer to 0.1ml of the conjugate. 
2.4 ELISA test procedure for detection of IgA 
Polystyrene flat-bottomed microtiter plate MTP (Nunc-immuno plate, 
Germany) were coated with 100µl of inactivated poliovirus Ag (105 
pfu/well) in coating buffer. Plates were kept at 40C over night. Then each 
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well in the MTP was washed with 200 µl washing buffer three times, after 
the last washing MTP were blotted on absorbent tissue or towel to dry the 
plates. To block non specific binding, 100µl of the blocking buffer was 
added to each well. Plates were left at room temperature for 30min washed 
and dried as described above. The first two rows of MTP were resolved for 
blank 3 positive controls and three negative controls, then 1/10 dilution of 
each saliva sample was dosified to the designated well. All plates were 
incubated for one hour at 370C, then the contents removed and plates were 
washed, dried as above. Hundred µl of 1/10000 dilution of the conjugate was 
added to each well except the blank. All plates were incubated at 370C for 
one hour and as previously mentioned, plates were washed and dried. 
Hundred µl of chromogen substrate was added to each well and incubation 
was done for 30min at room temperature. The enzymatic reaction was 
stopped by adding 100 µl of 1N HCL (stop solution) in the same sequence 
and time intervals for OPD. Brown colour developed and absorbance values 
(OD) were measured in ELISA plate reader (Rayto-RT6100, China), which 
was blanked at 492nm. 
2.5 Poliovirus specific serum IgG ELISA 
     The hundred serum samples kept at -200C ,negative and positive sera 
were allowed to reach RT before tested for the presence of poliovirus 
specific serum IgG Abs.  
2.5.1Prepration of poliovirus Ag 
     Heat inactivated OPV was adjusted to give a final concentration of 106 
pfu/ml as described in 2.3.2, this concentration was used for coating the 
microtitre plates. 
2.5.2Preparation of positive and negative control for serum IgG 
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     Three sera samples were selected from non-vaccinated individuals and 
included as negative control. Their low absorbance values were confirmed in 
pilot ELISA screening test.Likewise three serum samples from 
multivaccinated individuals were selected as positive control. In pilot ELISA 
screening test, the absorbance of these sera were found to be high. 
2.5.3 IgG Enzyme conjugate  
     Goat anti-Fc human IgG conjugated to horseradish peroxidase was 
obtained from Nordic Tilburg Holland code GAHu/IgG (H+L)/po. The 
conjugate was reconstituted by adding 1ml sterile distilled water to give a 
final dilution of 1/1000.This was further distributed in0.1ml volume in 
eppendorff tubes and kept at -200C. For performing the ELISA 1/10000 
dilution was prepared by adding 9.90ml dilution buffer to 0.1ml of the 
conjugate. 
2.5.4 The chromagen substrate 
     The OPD was prepared as described in 2.2.6. 
2.6 Test procedure for detection of IgG 
The test procedure is the same as described for detection of poliovirus 
salivary IgA except: 
1 Samples were serum. 
2 positive and negative controls also were sera samples. 
3 The conjugate was Goat antihuman IgG. 
2.7 Reading and interpretation of the test 
For validity of the assay it’s accomplished as described by Herrmann 
etal. , (2002).The presence or absence of anti-poliomyelitis virus IgA or IgG 
in saliva or sera respectively was determined by absorbance values of each 
sample. This value was the mean value obtained from the negative control 
saliva or sera plus 3 standard deviation .If the test value of a saliva or a 
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serum is about the calculated threshold absorbance value (mean+3SD), the 
saliva or serum samples were considered to be positive and if their test 
values were lower than the threshold value, the sample was considered as 
negative for the presence of poliomyelitis antibodies. 
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Chapter three 
Results 
 
3.1 Demographic characteristics of the study population  
     The study population was divided into three groups according to gender, 
age and area of residence within Omdurman municipality as shown in table 
(3.1).The prevalence of poliovirus specific salivary IgA and serum IgG as 
well as salivary IgA/serum IgG ratios are shown in the table (3.2). The 
prevalence of poliovirus Abs was expressed in absorbance values. 
 
3.2 The prevalence of poliovirus specific Abs in OPV immunized 
children in comparison with age, gender and area of residence.  
     High absorbance values of poliovirus specific IgA were obtained in saliva 
and sera of all immunized children studied as depicted in tables (3.3) and 
(3.4). Age, gender and area of residence had no significant effect on the 
level of SIgA as expressed in absorbance values for poliovirus specific SIgA 
(P = 0.2 - 0.38) as shown in table (3.3). 
 
3.3 Effect of age, gender and area of residence on the prevalence of 
poliovirus specific salivary IgA/ serum IgG absorbance ratios. 
     Although absorbance values for poliovirus specific salivary IgA were 
relatively high in comparison with serum IgG in the various groups, salivary 
IgA /serum IgG absorbance ratios according to age were not statistically 
significant (P =0.45), but salivary IgA /serum IgG absorbance ratio 
according to sex was statistically significant (P =0.03) and as shown in table 
(3.5). 
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3.4 The prevalence of poliovirus salivary IgA and serum IgG in various 
age groups of OPV immunized children. 
     The absorbance values of poliovirus specific salivary IgA and serum IgG 
were very high in all age groups as shown in fig. (3.1) and (3.2), tables (3.3) 
and (3.4) and the difference between these values among all age groups were 
not statistically significant (P = 0.36 for IgA and P =0.20 for IgG). In 
addition, salivary IgA /serum IgG absorbance values ratios were not 
statistically significant and P value was 0.45 as shown in fig. (3.3) table 
(3.5).These findings clearly showed that oral vaccination induced both local 
and systemic Ab responses.  
 
3.5 The prevalence of poliovirus specific salivary IgA and serum IgG in 
OPV immunized children according to gender. 
     Although high absorbance values for poliovirus specific salivary IgA 
were relatively high in comparison with poliovirus specific serum IgG in 
both sex, this difference is not statistically significant for both isotypes. The 
P value for SIgA was 0.294 and for serum IgG was 0.255 as shown in figure 
(3.4) and (3.5). However, the salivary IgA/ serum IgG absorbance ratio was 
higher in males than in females (P = 0.03) as shown in fig. (3.6). 
 
3.6 The prevalence of poliovirus specific salivary IgA and serum IgG in 
OPV immunized children according to area of residence. 
     Although absorbance values for poliovirus specific salivary IgA were 
relatively high compared to poliovirus specific serum IgG in children of 
various area of residence, this difference was not statistically significant in 
children of various area of residence for both isotypes ( P value for IgA = 
0.383 and for IgG =0.276) as shown in fig(3.7) and (3.8). However, salivary 
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IgA /serum IgG absorbance values ratios were statistically not significant (P 
= 0.058) according to area of residence as shown in fig. (3.9). 
 
3.7 Effect of OPV immunization on poliovirus specific salivary IgA and 
serum IgG. 
     A linear relationship between salivary IgA and serum IgG is depicted in 
fig. (3.10). This correlation is statistically significant (P = 0.00) and the 
graph clearly indicated that OPV immunization induced both local and 
systemic Ab response. 
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Table 3.1 Demographic characteristics of the study population. 
 
  Frequency % 
Gender Male 58 58 
 Female 42 42 
 Total  100 100 
    
Residence West-Omdurman 29 29 
 South-Omdurman 18 18 
 North-Omdurman 24 24 
  East north-Omdurman 9 9 
 Old Omdurman 20 20 
 Total 100 100 
    
Age ≤2 yrs 15 15 
 3 - 4 yrs 61 61 
 > 4 yrs 24 24 
 Total  100 100 
 
 
Mean age (±SD): 3.6 (±1.12) years 
Range (min - max): 1 - 7 years 
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Table 3.2 OD values determined by indirect ELISA for the measurement of 
the prevalence of poliovirus specific salivary IgA, serum IgG and salivary 
IgA / serum IgG absorbance ratio in OPV immunized subjects. 
 
Range   
Mean 
 
SD Minimum Maximum 
Serum Antibody 3.0 0.46 1.0 4.0 
Salivary Antibody 3.95 0.49 1.6 4.9 
Salivary/Serum Antibody Ratio 1.32 0.16 0.87 1.82 
OD mean and SD values of specific poliovirus salivary IgA and serum IgG 
antibodies among the study population. 
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Table 3.3 OD values determined by indirect ELISA for the measurement of 
the prevalence of poliovirus specific salivary IgA in relation to age, gender, 
and area of residence in OPV immunized children. 
95%CI    
 
P  
 
 
Mean 
 
 
SD 
Lower  
Bound 
Upper 
Bound 
Age ≤2 yrs 0.36 4.1 0.23 3.97 4.23 
 3 - 4 yrs  3.90 0.47 3.78 4.02 
 > 4 yrs  3.98 0.63 3.71 4.24 
       
Gender Male 0.29 3.99 0.43 3.88 4.11 
 Female  3.89 0.56 3.71 4.06 
       
Residence West-Omdurman 0.38 3.93 0.55 3.72 4.14 
 South-Omdurman  3.76 0.80 3.36 4.16 
 North-Omdurman  4.00 0.28 3.88 4.12 
  East north-Omdurman  4.10 0.27 3.89 4.31 
 Outside Omdurman  4.02 0.23 3.91 4.13 
Comparison of mean and 95% confidence interval of salivary IgA optical 
density in relation to demographic characteristics.  
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Table 3.4 OD values determined by indirect ELISA for the measurement of 
the prevalence of poliovirus specific serum IgG in relation to age, gender, 
and area of residence in OPV immunized children. 
95%CI    
 
P  
 
 
Mean 
 
 
SD 
Lower  
Bound 
Upper 
Bound 
Age ≤2 yrs 0.20 3.08 0.19 2.98 3.19 
 3 - 4 yrs  2.97 0.44 2.86 3.09 
 > 4 yrs  3.16 0.58 2.92 3.41 
       
Gender Male 0.25 2.99 0.39 2.89 3.09 
 Female  3.10 0.53 2.93 3.26 
       
Residence West-Omdurman 0.26 3.14 0.51 2.95 3.34 
 South-Omdurman  2.98 0.74 2.61 3.35 
 North-Omdurman  2.90 0.34 2.76 3.04 
  East north-Omdurman  3.19 0.16 3.06 3.31 
 Outside Omdurman  3.02 0.12 2.96 3.07 
Comparison of mean and 95% confidence interval of serum IgG optical 
density in relation to demographic characteristics.  
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Table 3.5 OD values determined by indirect ELISA for the measurement of 
the prevalence poliovirus specific salivary IgA/ serum IgG ratio in OPV 
immunized children. 
95%CI    
 
P  
 
 
Mean 
 
 
SD 
Lower  
Bound 
Upper 
Bound 
Age ≤2 yrs 0.45 1.34 0.11 1.27 1.40 
 3 - 4 yrs  1.33 0.17 1.29 1.37 
 > 4 yrs  1.28 0.19 1.20 1.36 
       
Gender Male 0.03 3.99 0.43 3.88 4.11 
 Female  3.89 0.56 3.71 4.06 
       
Residence West-Omdurman 0.058 3.93 0.55 3.72 4.14 
 South-Omdurman  3.76 0.80 3.36 4.16 
 North-Omdurman  4.00 0.28 3.88 4.12 
  East north-Omdurman  4.10 0.27 3.89 4.31 
 Outside Omdurman  4.02 0.23 3.91 4.13 
Comparison of mean and 95% confidence interval of salivary IgA/serum 
IgG ratio in relation to demographic characteristics.  
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Fig 3.1 OD values determined by indirect ELISA for the measurement of the 
prevalence of poliovirus specific salivary IgA in various age groups of OPV 
immunized children. 
 
 
Values of the mean and 95% CI of salivary antibody (optical density) in 
relation to age (P value = 0.36, statistically not significant). 
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Fig 3.2 OD values determined by indirect ELISA for the measurement of the 
prevalence of poliovirus specific serum IgG in various age groups of OPV 
immunized children. 
 
 
 
Values of the mean and the 95% CI of serum antibody (optical density) in 
relation to age (P value = 0.20, statistically not significant). 
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Fig 3.3 OD values determined by indirect ELISA for the measurement of the 
prevalence of salivary IgA/serum IgG absorbance values in the various age 
groups of OPV immunized children. 
 
 
 
Values of the mean and the 95% CI of salivary/ serum antibody ratio in 
relation to age (P value = 0.45, statistically not significant). 
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Fig 3.4 OD values determined by indirect ELISA for the measurement of the 
prevalence of poliovirus specific salivary IgA in various OPV immunized 
children according to gender. 
 
 
 
Values of the mean and the 95% CI of salivary antibody (optical density) in 
relation with gender (P value = 0.294, statistically not significant). 
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Fig 3.5 OD values determined by indirect ELISA for the measurement of the 
prevalence of poliovirus specific serum IgG in various OPV immunized 
children according to gender. 
 
 
 
Values of the mean and the 95% CI of serum antibody (optical density) in 
relation to gender (P value = 0.255, statistically not significant). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
2 
2.25
2.5 
2.75
3 
3.25
3.5 
Male Female
 
Se
ru
m
 A
nt
ib
od
y 
(O
pt
ic
al
 D
en
si
ty
) 
95%CI Upper Bound 
Mean 
95%CI Lower Bound 
 57
Fig 3.6 OD values determined by indirect ELISA for the measurement of the 
prevalence of poliovirus specific salivary IgA/ serum IgG absorbance values 
ratio in OPV immunized children according to gender.  
 
 
 
Values of the mean and the 95% CI of salivary/serum antibody ratio in 
relation to gender (P value = 0.03, statistically significant). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1 
1.15 
1.2 
1.25 
1.3 
1.35 
1.4 
1.45 
Male Female
 
Sa
liv
a\
Se
ru
m
 A
nt
ib
od
y 
R
at
io
 (O
pt
ic
al
D
en
si
ty
)  
95%CI Upper Bound 
Mean 
95%CI Lower Bound 
 58
Fig 3.7 OD values determined by indirect ELISA for the measurement of 
poliovirus specific salivary IgA in OPV immunized children according to 
area of residence. 
 
 
 
 
Values of the mean and the 95% CI of salivary antibody (optical density) in 
relation to residence (P value = 0.383, statistically not significant). 
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Fig 3.8 OD values determined by indirect ELISA for the measurement of the 
prevalence of poliovirus specific serum IgG in OPV immunized children 
according to area of residence. 
 
 
 
Values of the mean and the 95% CI of serum antibody (optical density) in 
relation to area of residence (P value = 0.276, statistically not significant). 
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Fig 3.9 OD values determined by indirect ELISA for the measurement of the 
prevalence of poliovirus salivary IgA/serum IgG absorbance values ratio in 
OPV immunized children according to area of residence. 
 
 
 
Values of the mean and the 95% CI of salivary/ serum antibody ratio in 
relation to area of residence (P value = 0.058, statistically not significant). 
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Fig 3.10 Linear relationship between salivary IgA and serum IgG antibody 
in various groups  
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Chapter four 
Discussion 
    
    4.1 Poliomyelitis is an acute viral infection which range in severity from 
non-specific illness to paralysis, human is the sole reservoir for poliovirus. 
Wild poliovirus spread directly or indirectly from person to person. 
     In the Sudan the trivalent OPV is used exclusively by the national 
vaccination programme. OPV vaccination programme was launched in 1994 
when the vaccine is offered to all newborn children and in the catch-up 
campaign targeted children up to 5years old. The Sudan annual 
immunization days have been conducted since 1994 with the view to 
eradicate poliomyelitis. The national and international commitment has 
enabled intensification and rapid expansion of polio-immunization 
programme in the Sudan, to meet the need for final stage of polio 
eradication. The implementation of house to house vaccination strategy has 
improved the campaign at local levels and the routine OPV3 coverage in 
2007 was 99% for children of 5 years. 
     Acute flaccid paralysis (AFP) surveillance started in the Sudan in 1995 to 
monitor clinical cases of poliomyelitis; but no serological test was 
implemented to evaluate the efficacy of the OPV and the level of protective 
immunity induced .In this study indirect in house ELISA was developed to 
monitor the humoral immune response to OPV. As both humoral and 
cellular immune response have been associated with poliovirus infection or 
vaccination, the antibody response is considered necessary in order to induce 
an immune state and protection (Ogra and Karzon, 1971). In this study OPV 
was found to induce SIgA at mucosal surfaces as measured by salivary IgA 
and at the same time induced serum IgG as depicted in table (3.2).The 
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absorbance values for both SIgA and serum IgG were very high with upper 
bound limit of 4.0 and lower bound limit of 2.0. Absorbance values were 
very high in all age groups fig. (3.1), (3.2). The absorbance values were 
proportional to the level of salivary IgA and serum IgG in our OPV 
immunized children. Persons are considered to be protected against 
poliomyelitis if they develop specific neutralizing antibodies ,however the 
level of serum neutralizing antibodies which protect against clinical illness 
has not been determined(Bodian and Nathanson,1960).Furthermore, it has 
been reported that persons with low serum neutralizing antibody titer against 
poliovirus can be infected with wild poliovirus .Nonetheless, in a pilot study 
5 fold rise two fold dilution for saliva and sera were made and gave a 
maximum and minimum absorbance values as included in appendixΠ .These 
findings are in agreement with WHO reports that proposed protective 
seroconversion in poliovirus immunized children should be 4 fold rise in 
neutralizing serum antibodies titer or just a change from seronegative to 
seroposative. 
     In this study known seroposative samples and known seronegative 
samples were run in each test. Cutoff value of colourmetric reaction was 
generated and the absorbance values of each test sample were compared 
against this value. 
     It is very intriguing to report that saliva and sera collected from a child 
with AFP (natural infection) gave absorbance values after the onset of 
paralysis similar to those OPV immunized children. These results are shown 
in appendix under patient number 74.This is a strong proof for the efficacy 
of OPV campaign.The vaccine mimics wild poliovirus infection by inducing 
serum neutralizing antibodies, as well as interferon and virus specific SIgA 
Abs in the pharynx and the gut and it is the protective Ig-isotypes at mucosal 
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surfaces (Yin&Almond, 2004).It's mechanism of action is through 
neutralization of virus and its neutralizing capacity is superior to other 
isotypes. This is because IgA is selectively excytosed at mucosal surfaces 
combining with poly –IgR at basal surfaces of columnar epithelial cells. The 
poly-IgR previously known as the secretory component that stabilize its 
structure and render it resistant to digestive enzymes. Moreover, OPV not 
only induce protective SIgA response at the same gut but also at distant 
mucosal sites. This why in our study we measured specific poliovirus IgA in 
saliva as a simple procedure for the measurement of protective immune 
response at the gut.This agreement with previous reports for other mucosal 
diseases (Ibrahim, 1984).This is also substantiating the previous work by 
Ogra, (1968) who reported that children may be resistant to poliovirus 
infection in absence of serum antibodies if the level of secretory antibodies 
is sufficiently high.  
     Furthermore, OPV induced production of serum IgG with high 
absorbance values and at this stage of intensified immunization programme 
it was found that in this study the difference in absorbance values for SIgA 
and serum IgG were not statistically significant (P value= 0.00) as depicted 
in fig (3.10), table (3.2).This is a second indicator that the expanded 
immunization programme conducted by the Federal Ministry of Health 
during the period 2005-2008 is extremely successful. The third indicator for 
the success of the campaign is that, the age has no significant effect on the 
result of the absorbance values as depicted in fig (3.1) (3.2) .On the other 
hand children receiving two or five doses of the OPV had the same 
absorbance values for salivary IgA and serum IgG as shown in appendix Π. 
Therefore, as the measurement of OPV efficacy is an ultimate test for 
protection i.e. prevention of paralytic poliomyelitis (AFP) in immunized 
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children as compared to none immunized one. However, despite the high 
level of salivary IgA and serum IgG in various age groups studied, its 
important to recognize that the number of samples studied was very small 
compared to the large scale study. For this reason screening for cases of AFP 
in vaccinated population can not be used as a single method to determine the 
absence of poliovirus circulation. On the other hand screening of poliovirus 
secretion is laboratory intensive and very insensitive as virus secretion last 
for only two weeks (Herrmans et al., 2002).Both criteria surveillance of AFP 
and virus isolation are being implemented in the Sudan .One case of 
poliomyelitis was detected in April 2001that led to an epidemics in fifteen 
states, and the wild virus was traced to be imported from neighboring Chad 
(CDC, 2000). In March 2008 another case of poliomyelitis was imported 
from Ethiopia and detected at Akobo in Jonglei state. The virus was 
confirmed as wild poliovirus P1 which is 96% close to poliovirus imported 
from Chad.Nonetheless, the expanded programme on immunization of the 
WHO has popularized the use of a particular cluster sample survey designed 
for developing countries for rapid assessment of vaccination coverage. 
However, in this study we developed an in-house ELISA for measurement 
of the absorbance values of specific poliovirus salivary IgA as well as serum 
IgG with the view in future to be a quantitative test in order to find the 
protective level of poliomyelitis Abs in body fluids. Our study also 
substantiate the findings of Herremans etal., (2002) who used IgA as 
serological marker for silent circulation of poliovirus in inactivated 
poliovirus vaccinated population in the Netherlands. Although our 
serological test does not discriminate between antibodies induced by 
vaccination or by infection by OPV strain or wild poliovirus, we anticipate 
that intensification of OPV campaign in the near future will reduce the 
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circulation of wild poliovirus in the population. This is because the virus 
replicate first at mucosal surfaces and induces the production of SIgA that 
will abrogate any new infection and hence stop excretion of the virus in the 
environment. Moreover, OPV is highly effective in producing immunity and 
a single dose of OPV produced immunity to all three serotypes in about 50% 
of the recipient and 3 doses of OPV induced immunity in more than 95% of 
the recipient which reported by Yin & Almond(2004). 
     Serum IgG antibodies against poliomyelitis are unable to limit primary 
viral replication in mucosal epithelium,however,they have been shown to 
neutralize poliovirus and prevent the production of disease state as reported 
in the case of IPV by Herrmaens etal (2002).In contrast OPV stimulate 
mucosal IgA and serum IgG as shown in fig.(3.10).Therefore the advantages 
of OPV through the production of mucosal IgA reduces the circulation of 
wild poliovirus in the population whereas IPV does not stop the circulation 
of wild poliovirus nor OPV strain in the population( Yin & Almond,2004). 
      Therefore, OPV armament the recipient with local and systemic Ab 
responses making it difficult for wild poliovirus to escape any of the two line 
of defense. The chief disadvantage of OPV is the occurrence of vaccine 
associated paralysis. However, this risk of paralytic poliomyelitis associated 
with reversion to neurovirulance as one case of paralysis for every two to 
four millions distributed doses of trivalent OPV (Yin & Almond, 2004). 
     For eradication of poliovirus to succeed, circulation of wild type 
poliovirus must cease completely and whether wild type poliovirus can 
remain circulating in vaccinated population, silent circulation is an important 
question for the eradication programme, especially in countries where IPV is 
in use. 
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Conclusions 
1- ELISA is useful technique to monitor Ab response in OPV immunized 
children. 
2- OPV immunization in childhood produce specific poliovirus mucosal 
IgA and systemic IgG Ab responses that detected in sera and saliva of 
vaccinated children. 
3- Age, gender and area of residence have no effect on the level of 
salivary IgA and serum IgG in OPV immunized children. 
4- A linear relationship was found between salivary IgA and serum IgG 
in OPV immunized children.Therefore, OPV immunization armament 
children with local and systemic Ab responses. 
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Recommendations 
1- Measurement of salivary IgA is a simple procedure for the estimation 
of mucosal immunity. 
2- The protective Ab level against poliomyelitis should be quantitated 
using standard reference saliva and sera in future studies. 
3- Indirect ELISA should be implemented to monitor the Ab response 
and the efficacy of the OPV immunization campaign. 
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Appendix Ι 
Questionnaire 
 
Khartoum University 
Collage of veterinary medicine 
Department of microbiology, Master programme 
Title of the project: poliomyelitis 
 
 
Name: …………………                        Residence: ………………… 
Age: …………………..                        Sex: ………………………… 
First vaccination: Yes (   ) No (   )                Date: ………………………… 
Second vaccination: Yes (   ) No (     )           Date: …………………………. 
Any other doses: …………….     Date: …………………………. 
Where he or she gets vaccinated: Home (  ) Clinic (  ) 
Infection with the disease: Yes (   )   No (  ) 
Date of infection: ……………………… 
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Appendix Π 
Absorbance values of salivary IgA at 1/10 and 1/180 dillutions: 
Saliva sample OD 1/180 OD 1/10 
1 2.9 3.5 
2 3.1 3.5 
3 3.3 3.9 
4 3.5 4.0 
5 3.2 3.9 
6 3.9 4.5 
7 3.1 4.0 
8 3.4 4.0 
9 3.4 4.1 
10 3.4 4.0 
11 3.2 4.0 
12 3.0 4.2 
13 2.7 3.2 
14 3.4 4.0 
15 3.8 4.2 
16 4.0 4.8 
17 3.8 4.5 
18 3.1 4.0 
19 3.6 4.0 
20 3.5 4.1 
21 3.9 4.5 
22 3.2 4.0 
23 0.9 1.6 
24 3.6 4.0 
25 3.8 4.2 
26 3.9 4.5 
27 3.2 4.0 
28 2.9 3.9 
29 3.0 3.9 
30 3.3 4.0 
31 0.8 1.8 
32 2.6 3.9 
33 4.0 4.6 
34 2.9 3.6 
35 3.7 4.1 
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36 3.1 4.0 
37 3.4 3.9 
38 3.6 4.0 
39 3.9 4.4 
40 3.4 3.9 
41 3.1 3.9 
42 3.5 3.9 
43 3.6 3.9 
44 3.5 4.0 
45 3.0 4.0 
46 0.9 1.6 
47 2.9 3.4 
48 2.9 3.9 
49 3.9 4.5 
50 3.8 4.0 
51 3.3 4.0 
52 3.3 4.0 
53 4.0 4.4 
54 3.2 3.8 
55 3.4 3.9 
56 3.5 4.0 
57 3.0 3.8 
58 2.7 3.5 
59 3.6 4.0 
60 3.1 3.9 
61 3.5 3.8 
62 3.2 4.0 
63 3.1 3.6 
64 3.4 3.9 
65 3.2 4.0 
66 3.5 4.0 
67 3.1 4.0 
68 3.5 4.1 
69 2.6 3.8 
70 3.3 4.0 
71 3.1 3.9 
72 3.6 4.0 
73 3.9 4.6 
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74*** 4.3 4.9 
75 2.9 3.4 
76 3.9 4.1 
77 3.7 4.0 
78 3.6 4.0 
79 3.8 4.3 
80 3.1 3.9 
81 3.3 3.8 
82 3.1 3.9 
83 3.2 4.0 
84 3.1 3.7 
85 3.6 4.1 
86 3.7 4.6 
87 3.6 4.0 
88 3.9 4.5 
89 3.0 4.0 
90 3.1 3.9 
91 3.6 3.9 
92 3.7 4.2 
93 3.1 4.0 
94 3.4 4.0 
95 3.8 4.2 
96 3.5 4.4 
97 3.7 4.0 
98 3.4 3.9 
99 3.6 4.0 
100 3.0 3.9 
 
*** AFP case 
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Absorbance values of serum IgG at 1/10 and 1/180 dillutions: 
Serum sample OD 1/180 OD 1/10 
1 2.9 3.9 
2 2.6 3.6 
3 2.4 3.6 
4 2.9 3.7 
5 2.4 3.0 
6 2.5 3.0 
7 2.7 3.1 
8 2.4 3.4 
9 2.0 3.0 
10 2.6 3.9 
11 2.3 3.0 
12 2.4 3.0 
13 2.6 3.2 
14 2.6 3.1 
15 2.9 3.3 
16 2.5 3.0 
17 2.4 3.0 
18 2.1 2.9 
19 2.2 2.9 
20 2.3 2.9 
21 2.9 3.3 
22 2.7 3.1 
23 0.5 1.0 
24 2.3 2.9 
25 2.7 3.2 
26 2.7 3.2 
27 2.5 3.0 
28 2.6 3.0 
29 2.9 3.4 
30 2.5 2.9 
31 0.9 1.2 
32 3.0 3.7 
33 2.1 2.9 
34 2.2 2.9 
35 2.4 2.9 
36 2.9 3.1 
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37 2.5 3.0 
38 2.6 3.0 
39 2.3 2.9 
40 2.9 3.3 
41 2.9 3.1 
42 2.4 2.9 
43 2.7 3.0 
44 2.9 3.3 
45 2.6 3.0 
46 0.7 1.2 
47 3.3 3.9 
48 3.0 3.5 
49 2.9 3.2 
50 2.8 3.3 
51 2.7 3.1 
52 2.5 2.9 
53 2.8 3.1 
54 2.7 3.1 
55 2.2 2.9 
56 2.6 3.0 
57 2.8 3.4 
58 2.7 3.0 
59 2.4 2.9 
60 2.6 3.0 
61 2.5 2.9 
62 2.9 3.4 
63 2.4 2.9 
64 2.6 3.0 
65 1.9 2.2 
66 2.0 2.9 
67 1.8 2.2 
68 2.8 3.0 
69 2.7 3.3 
70 1.6 2.2 
71 1.9 2.3 
72 2.5 2.9 
73 2.8 3.0 
74*** 3.3 4.0 
75 2.8 3.1 
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76 2.5 2.9 
77 2.3 2.9 
78 2.1 2.9 
79 2.7 3.2 
80 2.9 3.1 
81 2.6 3.1 
82 2.8 3.3 
83 2.7 3.1 
84 2.6 3.0 
85 2.8 3.2 
86 2.9 3.3 
87 2.7 3.3 
88 2.6 3.0 
89 2.7 3.2 
90 2.8 3.3 
91 2.0 3.0 
92 2.6 3.0 
93 2.5 3.0 
94 2.4 2.9 
95 2.1 2.9 
96 2.4 2.9 
97 2.6 2.9 
98 2.6 3.0 
99 2.7 3.0 
100 3.0 3.5 
 
 
*** AFP case 
 
 
 
 
 
 
 
